CN108350023B - Compound with anticancer effect and preparation method and application thereof - Google Patents
Compound with anticancer effect and preparation method and application thereof Download PDFInfo
- Publication number
- CN108350023B CN108350023B CN201680053558.3A CN201680053558A CN108350023B CN 108350023 B CN108350023 B CN 108350023B CN 201680053558 A CN201680053558 A CN 201680053558A CN 108350023 B CN108350023 B CN 108350023B
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- reduced pressure
- cancer
- under reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 72
- 230000001093 anti-cancer Effects 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title abstract description 49
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 99
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 31
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
- 201000007270 liver cancer Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 208000014018 liver neoplasm Diseases 0.000 claims description 16
- HOPVUIZLMIEGMJ-UHFFFAOYSA-N 2-(bromomethyl)-3,5,6-trimethylpyrazine Chemical compound CC1=NC(C)=C(CBr)N=C1C HOPVUIZLMIEGMJ-UHFFFAOYSA-N 0.000 claims description 11
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 229960004397 cyclophosphamide Drugs 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 abstract description 8
- 239000000651 prodrug Substances 0.000 abstract description 8
- 239000012453 solvate Substances 0.000 abstract description 8
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 68
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 68
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 67
- 210000004027 cell Anatomy 0.000 description 56
- 239000000203 mixture Substances 0.000 description 53
- 239000000243 solution Substances 0.000 description 50
- 239000007787 solid Substances 0.000 description 43
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 239000003208 petroleum Substances 0.000 description 33
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 32
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- 238000005303 weighing Methods 0.000 description 32
- 239000000741 silica gel Substances 0.000 description 31
- 229910002027 silica gel Inorganic materials 0.000 description 31
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- 238000002156 mixing Methods 0.000 description 28
- 238000012544 monitoring process Methods 0.000 description 28
- 125000003373 pyrazinyl group Chemical group 0.000 description 28
- 239000002994 raw material Substances 0.000 description 28
- 150000003431 steroids Chemical group 0.000 description 28
- 238000003756 stirring Methods 0.000 description 28
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 26
- 238000001704 evaporation Methods 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 238000001035 drying Methods 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 229940125773 compound 10 Drugs 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 18
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 16
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 13
- 239000004380 Cholic acid Substances 0.000 description 13
- 229960002471 cholic acid Drugs 0.000 description 13
- 235000019416 cholic acid Nutrition 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 229940090044 injection Drugs 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 12
- -1 deoxycholic acid benzyl ester Chemical class 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 8
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 8
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 8
- 229960003964 deoxycholic acid Drugs 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 7
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 229960001661 ursodiol Drugs 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 230000000155 isotopic effect Effects 0.000 description 6
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 5
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000003777 experimental drug Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 229940009456 adriamycin Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000001985 kidney epithelial cell Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000012996 alamarblue reagent Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000038561 Modiola caroliniana Species 0.000 description 1
- 235000010703 Modiola caroliniana Nutrition 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 235000011226 hei shi Nutrition 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a compound with a structure (I), a pharmaceutically acceptable salt, a stereoisomer, a solvate, a polymorph or a prodrug thereof, a preparation method thereof, and application of a pharmaceutical composition containing the compound in preparation of an anticancer drug.
Description
Technical Field
The invention relates to a compound and a preparation method and application thereof, in particular to a compound with selective anticancer activity and a preparation method and application thereof.
Background
The current clinical tragedies of 'death and death of cancer' often appear in the treatment of cancer, especially in various malignant canceration such as liver cancer, colon cancer, cervical cancer and the like, no specific medicine is available at present, the reason for this is that chemotherapy is one of the main modes of cancer at present, and first-line chemotherapeutic drugs often cause serious toxic and side effects to normal organisms while killing cancer cells, for example: nephrotoxicity, hepatotoxicity, neurotoxicity, and the like. The aim of obtaining the anti-Cancer medicine with high efficiency, low toxicity and strong selectivity is achieved by cumin of pharmaceutical workers, and the compound with strong cytotoxicity selectivity discovered by recent research at home and abroad has good druggability and accords with the development trend of modern precise medicine (Cancer Cell, 2015, 28, 240-252; int.J. mol.Sci.2015, 16(7), 16401-16413).
The compound is synthesized by chemical synthesis by taking cholic acid components with biological activities of resisting tumors and liver diseases, which mainly comprise Cholic Acid (CA), deoxycholic acid (DCA), ursodeoxycholic acid (UCA), hyodeoxycholic acid (HCA), chenodeoxycholic acid (CDCA), lithocholic acid (LCA) and a natural medicine ligustrazine (TMP) as starting raw materials. The activity evaluation of the compounds mainly surrounds the aspects of anti-tumor (especially liver cancer, intestinal cancer and the like), and the cytotoxic activity of the analogues on 4 cancer cell lines (HepG-2, HT-29, Hela, MCF-7), 9 primary liver cancer cell lines (HCC3787C1, HCC4172A2, HCC4477B2, HCC4484B1, HCC5850A1, HCC5864D1, HCC5953B1, HCC633A5 and HCC061A2) and non-cancer cell lines (NGF-induced PC12 cells, kidney epithelial cells MDCK and mouse embryo fibroblast 3T3) is tested respectively.
Disclosure of Invention
The first object of the present invention is to provide a compound having the structure of formula 1 and a method for preparing the same.
The second purpose of the invention is to provide the application of the compound in the formula 1 in preparing anti-cancer drugs.
The third purpose of the invention is to provide a medicament box with anticancer effect.
The purpose of the invention is realized by the following technical scheme:
a compound having the structure of formula 1, a pharmaceutically acceptable salt, stereoisomer, isotopic label, solvate, polymorph or prodrug thereof:
wherein R is1-R4Are independently-OH, -H or
Any one of the substituents;
r5 is-COOH,
Any one of the substituents;
and R is1-R5At least one of them
And (4) a substituent.
The present application further provides a pharmaceutical composition comprising a compound described herein above, a pharmaceutically acceptable salt, stereoisomer, isotopic label, solvate, polymorph or prodrug thereof, and a pharmaceutically acceptable carrier. The pharmaceutical composition includes, but is not limited to, oral dosage forms, parenteral dosage forms, topical dosage forms, and rectal dosage forms. In some embodiments, the pharmaceutical composition may be a tablet, capsule, pill, powder, sustained release formulation, solution or suspension for oral administration, a sterile solution, suspension or emulsion for parenteral injection, an ointment or cream for topical application, or a suppository for rectal administration.
The preparation method of the compound comprises the following steps:
scheme 1: dissolving cholic acid components in an organic solvent, and reacting with 2-bromomethyl-3, 5, 6-trimethylpyrazine (an intermediate compound 1) under an alkaline condition to obtain a compound I;
the compound I further reacts with ligustrazine acid (an intermediate compound 2) under the action of a catalyst and a condensing agent to obtain a compound II.
The reaction route is as follows:
reaction conditions and reagents: (a) benzene, reflux, 10 h; (b) CCl4，NBS，hv，reflux， 12h；(c)DMF，K2CO3，N2，85℃，1.5h；(d)H2O，KMnO4，37℃，6h；(e)dry CH2Cl2，EDCI，DMAP，12h。
Wherein, R in the compound I1-R4Are each-OH or-H, and R1、R2、R4At least one-OH group;
in compound II R3is-OH or-H, R1、R2、R4Are independently-OH, -H or
And R is1、R2、R4At least one of them
The specific structure of each compound is shown in Table 1.
TABLE 1 Compound I and II structural formulas
Scheme 2: dissolving cholic acid components in an organic solvent, and reacting with benzyl bromide under an alkaline condition to obtain an intermediate compound 3; the intermediate compound 3 further reacts with ligustrazine acid (intermediate compound 2) under the action of a catalyst and a condensing agent to obtain a compound III; the compound III is further reduced by hydrogen to obtain the compound IV of the invention.
The reaction route is as follows:
a，THF，Reflux，K2CO3；b，CH2Cl2，EDCI/DMAP，c，THF，Pd/C，Pd(OH)2/C
wherein, R in the compounds III and IV3is-OH or-H, R1、R2、R4Are independently-OH, -H or
And R is1、R2、R4At least one of them
The specific structure of each compound is shown in Table 2.
TABLE 2 Compound III and IV structural formulas
Further, the above reaction is carried out at-20 ℃ to 250 ℃; the organic solvent is ether, alcohol, alkane, aromatic hydrocarbon, ketone, alkyl halide, amide, nitrile, ester or their mixture in various proportion containing 1-20 carbon atoms; the alkali is triethylamine or potassium carbonate; the catalyst is 1-Hydroxybenzotriazole (HOBT); the condensing agent is any one or more of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI), 1, 3-Dicyclohexylcarbodiimide (DCC) or 4-Dimethylaminopyridine (DMAP).
Further, in the preparation method, the molar ratio of the cholic acid component to the 2-bromomethyl-3, 5, 6-trimethylpyrazine (intermediate compound 1) is 1: 0.1-1: 10; the molar ratio of the cholic acid component to the alkali is 1: 0.1-1: 10; the mol ratio of the compound II to the ligustrazine acid (the intermediate compound 2) is 1: 0.1-1: 10; the molar ratio of the compound II to the condensing agent is 1: 0.1-1: 10; the molar ratio of the catalyst to the catalyst is 1: 0.1-1: 10.
The invention also provides application of the compound shown in the formula 1, pharmaceutically acceptable salt, stereoisomer, isotopic marker, solvate, polymorph or prodrug thereof in preparing an anticancer drug.
Further, the cancer is liver cancer, colon cancer, cervical cancer, breast cancer.
The present invention also provides a method of treating cancer, comprising administering to a subject in need thereof an effective amount of a compound of formula 1, or a pharmaceutically acceptable salt, stereoisomer, isotopic label, solvate, polymorph or prodrug thereof. The subject may be a mammal, such as a human.
Further, the effective amount of the compound of formula 1 or a pharmaceutically acceptable salt, stereoisomer, isotopic label, solvate, polymorph or prodrug thereof is 1-10 mg/kg-day.
Further, the cancer is liver cancer, colon cancer, cervical cancer, breast cancer.
In some embodiments, the pharmaceutical composition and the at least one therapeutic agent are combined into a combination product, such as a kit, in separate dosage forms. The combination product comprises 1-10 mg/kg-day of effective dose of therapeutically effective dose of compound shown in formula 1 or pharmaceutically acceptable salt, stereoisomer, isotope label, solvate, polymorph or prodrug thereof.
Further, the anticancer drug is one or more of cyclophosphamide, 5-fluorouracil, paclitaxel, adriamycin, etoposide, irinotecan, oxaliplatin, cisplatin or jiaojian.
The term "pharmaceutically acceptable" as used herein refers to molecular entities and compositions that are physiologically tolerable and do not typically produce allergic or similar untoward reactions when used in humans. The "therapeutically effective amount" refers to an amount of drug administered sufficient to cause an improvement in a clinically significant condition/symptom in the host. The term "solvate" refers to a combination of a compound of the present application and a solvent molecule formed by solvation. The "polymorphs" refer to the compounds of the present application in different crystal lattice forms. The term "isotopic label" refers to a compound of the present application which is labeled with an isotope. The term "pharmaceutically acceptable prodrug" refers to any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of the present application that, upon administration to a recipient, is capable of providing, directly or indirectly, a compound of the present application or a pharmaceutically active metabolite or residue thereof. The term "stereoisomer" refers to an isomer resulting from the difference in the arrangement of atoms in a molecule.
The compound has an inhibiting effect on various cancer cells, the tumor inhibition rate of 30mg/kg by intraperitoneal injection on H22 tumor-bearing mice reaches 60.16 percent, and the tumor inhibition rate is equivalent to that of a positive medicament cyclophosphamide; has little toxicity to normal cells such as nerve cells, kidney cells, mouse embryo fibroblasts and the like, and normal mice are injected with LD in the abdominal cavity50More than 900mg/kg, indicating that the medicine has high safetyIt can be used for preventing and treating cancers such as hepatocarcinoma, intestinal cancer, and cervical cancer.
Experimental example 1 AlamarBlue method for observing the effect of the composition of the present invention on the proliferation of cancer cells and non-cancer cell lines
1. Apparatus and materials
Thermo 311 type CO2An incubator; a Haier biosafety cabinet; molecular Devices microplate reader; hunan instrumental L530 type desk type low-speed centrifuge; olympus IX51 inverted fluorescence microscope, RPMI-1640 medium, fetal bovine serum, 0.25% trypsin solution, phosphate buffer (seimer heisha shanghai ltd); sigma dimethyl sulfoxide (DMSO), resazurin;
human breast cancer cell line MCF-7; a human hepatoma cell line HepG-2; mouse embryonic fibroblast 3T 3; human colon cancer cell lines HT-29; human cervical cancer cell line Hela; canine kidney epithelial cells MDCK; mouse adrenal chromophagous tumor cell PC 12;
experimental drugs: compounds (1-30) of the present invention (prepared as in examples 3-32); ligustrazine (TMP), Cholic Acid (CA), deoxycholic acid (DCA), ursodeoxycholic acid (UCA), hyodeoxycholic acid (HCA), chenodeoxycholic acid (CDCA), lithocholic acid (LCA); the positive drug, Doxorubicin (Doxorubicin) (HY-15142; Haoyuan, Shanghai, Biomedicine technology, Inc.).
2. Method of producing a composite material
2.1 culture of different cell lines
MCF-7, HepG2, 3T3, HT-29, Hela, MDCK and NGF-PC12 cells are cultured in 1640 culture solution containing 10% fetal calf serum and placed at 37 ℃ in 5% CO2Incubation in an incubator. The cells all grow in an adherent state, the growth condition is observed under an inverted microscope, and subculture is carried out when the number of the cells is proper.
2.2 inhibition of tumor cell proliferation and Normal cell proliferation
Cell testing: MCF-7, HepG2, HT-29, Hela, 3T3, MDCK and NGF-PC12 cells in a logarithmic growth phase are inoculated into a 96-well culture plate in the number of 3 x 103/well, 10 mu L of a compound to be tested or a positive drug is added into each well after the cells are cultured for 4 hours at 37 ℃ in a humidified incubator containing 5% CO2, and the concentration of 9 drugs is tested, so that the final drug concentration is respectively 100, 31.6, 10, 3.16, 1, 0.31, 0.1, 0.03 and 0.01 mu M. Setting a positive control group (100% inhibition) and a negative control group (0% inhibition), repeating the concentration of the drug group for 2 holes, repeating the concentration of the positive control group and the concentration of the negative control group for 6 holes, and carrying out subsequent AlamarBlue test operation after continuously culturing in an incubator for 6 days;
AlamarBlue test procedure: adding 10 mu L of AlamarBlue reagent into each well, incubating for 1-4h, oscillating for 1-2min, and performing enzyme labeling on MD (enzyme labeling) instrument EX: 560nm, EM: measuring fluorescence value at 590nm wavelength, recording the result, calculating the cell inhibition rate (%) of the drug (A0% inhibition-A administration)/(A0% inhibition-A100% inhibition). times.100%, and drawing by using GraphPad Prism 5.0 or MATILAB software and adopting a nonlinear regression method (usually adopting a four-parameter fitting curve equation) to obtain a drug dose response curve, thereby obtaining the IC of the compound50Values and other relevant parameters.
3. Results
3.1 the IC50 values of the compounds of the invention on 5 tumor cell lines (MCF-7, HepG2, HT-29, Hela) and normal cells (3T3, MDCK, NGF-induced PC12) are shown in Table 3.
TABLE 3 IC of different drugs on tumor cell lines and normal cells50Value of
Note that: "-" indicates: according to the result of the cytotoxicity test, when the effect on cancer cells is not obvious, the activity is considered to be low, and the cytotoxicity test on non-cancer cells is not carried out.
As can be seen from Table 3, the compound of the present invention shows proliferation inhibitory activity on various cancer cells, especially compound 10, which has antitumor activity superior to that of the raw material, and antiproliferative activity superior to that of the positive drug adriamycin on human colon cancer cell line HT-29 and human cervical cancer cell line Hela; and the cytotoxicity to NGF-induced PC12 cells, canine kidney epithelial cells MDCK and mouse embryonic fibroblasts 3T3 is obviously lower than that of the positive drug adriamycin.
4. Conclusion
The compound of the invention has better inhibitory activity (IC) on various cancer cells50< 5.7. mu.M), but without any killing effect (IC) on a variety of normal cells at higher doses50More than 80 mu M), has good cytotoxicity selectivity effect.
Experimental example 2 AlamarBlue method for observing the effect of the present invention on proliferation of hepatoma cells and evaluation of response rate in hepatoma
1. Apparatus and materials
Thermo 311 type CO2An incubator; a Haier biosafety cabinet; molecular Devices microplate reader; hunan instrumental L530 type desk type low-speed centrifuge; olympus IX51 inverted fluorescence microscope, DMEM/F12 medium, fetal bovine serum, 0.25% trypsin solution, phosphate buffer (seimer heishi shanghai ltd); sigma dimethyl sulfoxide (DMSO), resazurin;
liver cancer tissues from independent 9 liver cancer patients were prepared into 9 primary liver cancer cell lines (human liver cancer cell lines HCC3787C1, HCC4172a2, HCC4477B2, HCC4484B1, HCC5850a1, HCC5864D1, HCC5953B1, HCC633a5, and HCC061a2) as follows: fresh liver cancer tissues after surgical resection are taken and cleaned in PBS (GIBCO, 10010-23), are cut into small pieces of 0.5-1mm3 by using instruments such as ophthalmological forceps, scissors and the like in a100 mm culture dish and are laid at the bottom of the dish, 10ml of DMEM/F12 cell culture medium (GIBCO, 11320-containing 033) containing 10% FBS (GIBCO, 10099-containing 141) and 1% Pen-Strep antibiotic (GIBCO, 15140-containing 122) is added into the culture dish, and the culture is carried out in a culture box of 5% CO2 at 37 ℃. The next day, cells were observed under an inverted microscope to migrate from around the tissue mass and then gradually extended to develop into a halo of growth that was visible to the naked eye. After 5-7 days, the histiocytes in the center of the tissue block gradually die and fall off and float, the floating small block can be discarded along with the change of the liquid, and the adherent cells extending from the periphery of the tissue block also gradually form a layer slice. Using the difference in the digestion capacity between fibroblasts and tumor cells, the cells were digested with 0.25% trypsin solution (GIBCO, 25200056) and subcultured to remove fibroblasts continuously. After multiple passages, fibroblasts cannot be observed in the culture dish by naked eyes, and can be used for subsequent experiments when the cells can continuously grow and passages.
Experimental drugs: the compound of the invention (prepared as in example 10); the chemotherapeutic drug Doxorubicin (Doxorubicin) (HY-15142; Shanghai Haoyuan biomedical science, Inc.).
2. Method of producing a composite material
2.1 culture of different cell lines
9 liver cancer cell lines HCC3787C1, HCC4172A2, HCC4477B2, HCC4484B1, HCC5850A1, HCC5864D1, HCC5953B1, HCC633A5 and HCC061A2 are cultured in DMEM/F12 culture solution containing 10% fetal calf serum, placed at 37 ℃ and 5% CO2Incubation in an incubator. The cells grow in an adherent state, the growth condition is observed under an inverted microscope, and subculture is carried out when the cell confluence rate reaches 80% -90%. The subculture proportion and the number of the hepatoma cell lines are determined according to experimental requirements, and the subculture proportion of the hepatoma cell lines is generally 1: 2-1: 3.
2.2 proliferation inhibition of different hepatoma tumor cell lines
Cell testing: taking 9 liver cancer cell lines HCC3787C1, HCC4172A2, HCC4477B2, HCC4484B1, HCC5850A1, HCC5864D1, HCC5953B1, HCC633A5 and HCC061A2 in logarithmic growth phase, and carrying out reaction at a speed of 1-3 × 103Per well (optimal density of inoculations per hepatoma cell line determined in preliminary experiments) were plated in 96-well plates in 5% CO2After 4 hours of culture at 37 ℃ in a humidified incubator, 10. mu.L of the compound of the invention was added to each well, 9 drug concentrations were tested, and the final drug concentrations were made to be 100, 31.6, 10, 3.1, 1, 0.3, 0.1, 0.03, and 0.01. mu.M, respectively, and a QC reference compound, Doxorubicin, was added simultaneously at the time of testing each hepatoma cell line, and the final drug concentrations were 10, 3.16, 1, 0.31, 0.1, 0.03, 0.01, 0.003, and 0.001. mu.M, respectively. In addition, a positive control group (100% inhibition) and a negative control group (0% inhibition) are simultaneously arranged, 2 holes are repeated for each concentration of the medicine group, 6 holes are repeated for the positive control group and the negative control group, and after the positive control group and the negative control group are continuously cultured in an incubator for 6 days, the subsequent AlamarBlue test operation is carried out;
AlamarBlue test procedure: adding 10 mu L of AlamarBlue reagent into each well, incubating for 1-4h, oscillating for 1-2min, and performing enzyme labeling on MD (enzyme labeling) instrument EX: 560nm, EM: the fluorescence value was measured at 590nm wavelength, and the results were recorded, and the cell inhibition ratio (%) of the compound of the present invention was calculated as (A)0% inhibition-AAdministration of drugs)/(A0% inhibition-A100% inhibition) X 100%, and then drawing by using GraphPad Prism 5.0 or MATILAB software and adopting a nonlinear regression method (usually adopting a four-parameter fitting curve equation) to obtain a drug dose response curve, thereby obtaining the IC of the compound acting on 9 hepatoma cell lines50The value is obtained.
3. Results
3.1 IC of Compound 10 of the present invention against 9 liver cancer cell lines (HCC3787C1, HCC4172A2, HCC4477B2, HCC4484B1, HCC5850A1, HCC5864D1, HCC5953B1, HCC633A5 and HCC061A2)50The values are shown in Table 4.
TABLE 4 IC of Compound 10 of the present invention against 9 hepatoma cell lines50Value of
As can be seen from Table 4, Compound 10 of the present invention has a better inhibitory activity (IC) against 7 liver cancer cell lines (HCC4477B2, HCC4484B1, HCC5850A1, HCC5864D1, HCC5953B1, HCC633A5 and HCC061A2)50< 10. mu.M), inhibitory activity IC against 2 liver cancer cell lines HCC4172A2 and HCC3787C150About 10 μ M. Therefore, the compound has good effect of inhibiting the proliferation of the liver cancer cells and has good response rate in the liver cancer cells
Experimental example 3 anti-tumor Effect of Compound 10 of the present invention on H22 sarcoma mouse
1. Material
1.1 Experimental animals and tumor strains:
healthy male ICR mice, weighing 18-22g, were purchased from the laboratory animal center of Wintolite laboratory animal technology corporation (certification code SCXK (Jing) 2011-; mouse sarcoma cell H22 was obtained as a gift from the university of Western Ann traffic. Tumor-bearing H22 mice, passaged every 5 days.
1.2 Experimental drugs:
the purity of the compound 10 is determined by liquid chromatography (HPLC) analysis, and is more than or equal to 98 percent, thereby meeting the experimental requirements. The powder was stored sealed at 4 ℃.
Cyclophosphamide for injection: shanxi Pude pharmaceutical Co., Ltd (production batch: 04140202)
2. Method of producing a composite material
2.1 model animal construction
Killing inoculated 7-day H22 mouse by breaking neck, respectively taking ascites under aseptic condition, washing with RPMI1640 culture medium for 2 times, and making into 2 × 10 with sterile physiological saline7The cell suspension/ml, H22 cell suspension was inoculated under the skin of the right axilla of mice, 0.1ml each, 72 were inoculated, and solid tumor models were prepared.
2.2 Experimental groups
The 72 mice were randomly divided into 6 groups by weight, namely a normal control group, a positive drug (cyclophosphamide) group, a model group, a low dose group, a medium dose group and a high dose group of the compound of the present invention; each group had 12.
2.3 methods of administration
The compound 10 is prepared from soybean oil for injection, the dosage of a low-dose group is 10mg/kg, the dosage of a medium-dose group is 30mg/kg, the dosage of a high-dose group is 90mg/kg, a negative control group is injected with soybean oil for injection with equal volume, a positive control group is injected with cyclophosphamide injection 30mg/kg, every other day is injected with abdominal cavity, and the continuous administration is carried out for 12 days. During the period, the mice were observed daily for general activities, fur, feces, body weight, and the like. 24H after the last dose, mice vaccinated subcutaneously with H22 were sacrificed by cervical amputation and tumor, liver, spleen and kidney were removed.
2.4 calculation of visceral index
After the administration of all the solid tumor groups, the mice were weighed and then sacrificed, and the spleen, kidney and liver were weighed using an electronic balance, respectively. The spleen index is the weight of spleen (mg)/weight of mouse (g) of each group of mice, the liver index is the weight of liver (100 g)/weight of mouse (g), and the kidney index is the weight of kidney (mg)/weight of mouse (g).
2.5 calculation of tumor inhibition Rate
The solid tumor negative control group is weighed the next day after drug withdrawal, (eyeball bleeding is removed, serum is collected for subsequent experiments) the mice are killed after being taken out of the neck, tumor tissues are dissected, weighing is carried out by an electronic balance, and the tumor inhibition rate is calculated.
2.6 statistical treatment
All data are statistically analyzed by SPSS11.0 software package, and the comparison of counting data is performed by x2And (6) checking. P is less than 0.05, which has statistical significance.
3. Results
3.1 in vivo anticancer Activity of Compound 10 of the present invention
The results are shown in Table 5.
TABLE 5 inhibitory Effect of Compound 10 of the present invention on H22 tumor-bearing mice (x. + -. s)
Note: comparison with normal controls: p < 0.05, P < 0.01
As shown in Table 5, the compound 10 has no influence on the weight gain of H22 sarcoma mice, and has obvious tumor inhibiting effect, the tumor growth inhibiting rates of the low, medium and high dose groups to H22 sarcoma mice are 46.09%, 60.16% and 50.78%, respectively, and the tumor inhibiting effect of the high dose group is equivalent to that of the positive drug cyclophosphamide.
3.2 changes in liver, spleen and Kidney indices of various groups of H22 mice
The results are shown in Table 6.
TABLE 6 Effect of Compound 10 of the present invention on the liver, spleen and Kidney indices (x + s) of H22 mice
Note: comparison with blank control group: p < 0.05, P < 0.01
As shown in Table 6, compared with the normal control group, the liver-spleen index of the model group is increased, the spleen index change is particularly obvious (P is less than 0.05), and the kidney index is reduced. After treatment, cyclophosphamide and the compound can reduce the liver and spleen indexes of H22 sarcoma mice to be close to normal levels.
4. Conclusion
4.1 Compound 10 of the present invention significantly inhibited the growth of H22 mouse sarcoma.
4.2 Compound 10 of the present invention modulates the liver and spleen index of H22 sarcoma mice.
Experimental example 4 acute toxicity test of Compound 10 of the present invention
1. Material
1.1 Experimental animals
Healthy ICR mice, each male and female 12, with a weight of 18-22g, purchased from the laboratory animal center of Wintonlihua laboratory animal technology company (certificate number SCXK (Jing) 2006-0009)
1.2 Experimental drugs
The purity of the compound 10 is determined by liquid chromatography (HPLC) analysis, and is more than or equal to 98 percent, thereby meeting the experimental requirements. The powder was stored sealed at 4 ℃. Dissolving 450mg of the compound in appropriate amount of ethyl acetate, mixing with 5.0ml of soybean oil for injection, and ultrasonic suspending, and recovering ethyl acetate as solvent until it is odorless. It is prepared as before use.
2. Method of producing a composite material
40 mice were randomly divided into 4 groups of 10 mice each based on body weight, the experimental group was administered by intraperitoneal injection of mice, and the control group was administered with the same amount of soybean oil for injection. Mice were fasted overnight (12 hours continuously) prior to dosing, and at 9 am of the day: 00 (900mg/kg) was started and was fed after 6 hours of continuous observation for 14 days.
3. Results
After the intraperitoneal injection administration (900mg/kg), slight writhing phenomenon appears in individual mice, symptoms disappear within 1 hour approximately, death is not seen within 12 hours after the administration, and no obvious toxic and side effects are seen in blank groups. After 14 days, the state of each group of mice is good, no death is seen, and no abnormal change is seen when visceral organs such as heart, liver, spleen, lung, kidney, adrenal gland, thyroid gland and the like are observed after the cervical vertebra dislocation of the mice is died. Acute toxicity test of compound 26 injected in abdominal cavity of mouse shows that the medicine LD50＞900mg/kg。
4. Conclusion
Compound 10 of the present invention is injected into normal mouse abdominal cavity with LD50More than 900mg/kg, and higher safety.
Detailed Description
EXAMPLE 12 preparation of bromomethyl-3, 5, 6-trimethylpyrazine (intermediate Compound 1)
According to optimization of a synthesis process of an intermediate 2-bromomethyl-3, 5, 6-trimethyl pyrazine, introduction, Rongpenlong, Hanqijun, and the like, Anhui medicine, 2013, 17 (9): 1467-1470' method. Weighing 20.00g (0.15mol) of anhydrous ligustrazine and 23.54g of NBS N-bromosuccinimide (0.15mol, ground before use) in a 250mL three-necked flask, 100mL CCl4As a reaction solvent, 4 incandescent lamps of 85W were used for irradiation, and the reaction was refluxed at 95 ℃ for 1 hour. TLC (3: 1 ratio of V (petroleum ether) to V (acetone))]The detection reaction is substantially complete; cooling, filtering, collecting filtrate, and recovering solvent under reduced pressure to obtain mauve viscous liquid (content is 60%). HRMS (ESI) m/z: 216.00135[ M + H]+，calcd.for C8H11BrN2 216.00851。
Example 23 preparation of 5, 6-trimethylpyrazine-2-carboxylic acid (intermediate Compound 2)
According to "the synthesis of novel ligustrazine derivatives and the study of their anticancer activity", journal of northwest pharmacology, 29 (1): 58-64' method. 10.0g (73.53mmol) of ligustrazine is suspended in 100.0mL of distilled water, 11.62g (73.53mmol) of potassium permanganate is weighed and added in 3 batches, and the mixture is magnetically stirred at 37 ℃ for 24 hours. Cooling the mixed solution, performing suction filtration, adjusting the pH of the filtrate to 1-2 by using 360 mg.L < -1 > hydrochloric acid, extracting for 3 times by using ethyl acetate, collecting an ethyl acetate layer, drying by using anhydrous sodium sulfate, concentrating under reduced pressure to dryness, and recrystallizing by using acetone to obtain a white solid, wherein the yield is as follows: 47.8%, m.p.: 162 ℃ and 163 ℃.
EXAMPLE 3 preparation of Compound 1
Weighing 2.19mmol of 2-bromomethyl-3, 5, 6-trimethyl pyrazine and 2.19mmol of deoxycholic acid, placing the materials in a 50ml round-bottom flask, adding 25ml of DMF, adding 3mmol of potassium carbonate after the mixture is dissolved, stirring at 85 ℃ for 2h, monitoring by TLC that the reaction raw materials basically disappear, stopping the reaction, adding a large amount of saturated NaCl solution into the reaction solution for dispersion, extracting by 300ml of ethyl acetate twice, and using anhydrous Na for an ethyl acetate layer2SO4Drying, concentrating under reduced pressure, dissolving the residue with 3ml chloroform, adding 2.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 8: 1 to obtain white solid 0.594 g. m.p.: 83.6-84.3 ℃, yield 58.4%. HRMS (ESI) m/z: 527.5201[ M + H]+，calcd.for C32H51N2O4 527.3849.
EXAMPLE 4 preparation of Compound 2
Weighing 11.2mmol of compound and 1.8mmol of ligustrazine acid, placing in a 50ml round bottom flask, adding 25ml of CH2Cl2After the mixture is dissolved, EDCI 1.8mmol and DMAP 0.18mmol are respectively added, the mixture is stirred for 12h at room temperature, TLC monitors that the reaction raw materials basically disappear, the reaction is stopped, the mixture is concentrated under reduced pressure, 2.2g of silica gel is added, the mixture is evaporated to dryness under reduced pressure and is mixed with a sample, and an eluant is petroleum ether and acetone which are 7: 1 to elute, so that 0.426g of white solid is obtained. White Amorphous solid, m.p.: 60.5-61.2 ℃ and yield 52.7 percent.1H-NMR(CDCl3)(ppm)：0.67(s，3H，H-18)，0.96(s，3H，H-19)，0.97(d，J＝ 7.0Hz，3H，H-21)，3.99(m，1H，H-12)，5.04(m，1H，H-3)，5.19(t，J＝12.5 Hz，2H，CH2-2′)，2.72(s，3H，CH3-6″)，2.57(s，3H，CH3-5″)，2.56(s，3H， CH3-3″)，2.54(s，3H，CH3-6′)，2.52(s，3H，CH3-5′)，2.51(s，3H，CH3-3′)， 1.00-2.50(27H，methyl-and methylene-of steroid structure).13C-NMR (CDCl3)(ppm)：35.0(C1)，26.5(C2)，76.2(C3)，32.1(C4)，42.0(C5)，27.0 (C6)，26.0(C7)，36.0(C8)，33.7(C9)，34.2(C10)，28.7(C11)，73.1(C12)， 46.5(C13)，48.2(C14)，23.6(C15)，27.4(C16)，47.3(C17)，12.7(C18)，23.1 (C19)，35.1(C20)，17.3(C21)，31.1(C22)，30.9(C23)，173.8(C24)；pyrazine ring：64.9(2′-CH2)，151.2(C2′)，144.9(C3′)，148.9(C5′)，149.1(C6′)，166.8 (2″-C＝O)，154.5(C2″)，140.4(C3″)，149.3(C5″)，150.5(C6″)，21.6(6′-CH3)， 21.4(5′-CH3)，20.4(3′-CH3)，22.5(6″-CH3)，22.1(5″-CH3)，21.6(3″-CH3). HRMS(ESI)m/z：675.44635[M+H]+，calcd.for C40H58N4O5 674.44072.
Preparation of intermediate deoxycholic acid benzyl ester: weighing benzyl bromide 5.0mmol and deoxycholic acid 5.0mmol, placing in 50ml round bottom flask, adding 25ml DMF, dissolving the mixture, adding 5mmol potassium carbonate, stirring at 85 deg.C for 2h, monitoring by TLC that the reaction raw materials basically disappear, stopping the reaction, adding a large amount of saturated NaCl solution into the reaction solution for dispersion, extracting twice with 400ml ethyl acetate, and using anhydrous Na for ethyl acetate layer2SO4Drying, concentrating under reduced pressure, dissolving the residue with 5ml chloroform, adding 3.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 5: 1 to obtain white solid 2.212 g. White powder, m.p.: 136.5-137.3 ℃ and yield 91.8 percent.
EXAMPLE 5 preparation of Compound 3
Weighing deoxycholic acid benzyl ester 3.0mmol, 4.0mmol of ligustrazine acid are placed in a 50ml round bottom flask, 30ml of CH is added2Cl2After the mixture is dissolved, respectively adding EDCI 4.0mmol and DMAP 0.4mmol, stirring at room temperature for 12h, monitoring by TLC that the reaction raw material basically disappears, stopping the reaction, washing the reaction solution twice by 60ml of saturated NaCl solution, and obtaining CH2Cl2The layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, added with 3.2g silica gel, evaporated to dryness under reduced pressure and mixed with the eluent petroleum ether and acetone at 7: 1 to give 0.924g white solid. White Amorphous solid, m.p.: 47.1-48.0 ℃ and yield 48.9 percent.1H-NMR(CDCl3)(ppm)：0.67(s，3H，H-18)，0.97(s，3H，H-19)，0.98 (d，J＝7.5Hz，3H，H-21)，3.99(m，1H，H-12)，5.05(m，1H，H-3)，5.14，5.11 (ea，d，J＝12.5Hz，1H，CH2-1′)，7.37(m，5H，H-2′，3′，4′，5′，6′)，2.72(s，3H， CH3-6″)，2.58(s，3H，CH3-5″)，2.57(s，3H，CH3-3″)，1.00-2.50(27H，methyl- and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.0(C1)， 26.5(C2)，76.2(C3)，32.3(C4)，42.1(C5)，27.0(C6)，26.1(C7)，36.0(C8)， 33.7(C9)，34.2(C10)，28.7(C11)，73.1(C12)，46.5(C13)，48.2(C14)，23.6 (C15)，27.4(C16)，47.5(C17)，12.7(C18)，23.1(C19)，35.0(C20)，17.3 (C21)，31.3(C22)，30.9(C23)，174.0(C24)，66.1(1′-CH2)，136.1(C1′)，128.2 (C2′，6′)，128.5(C3′，5′)，128.2(C4′)；pyrazine ring：165.8(2″-C＝O)，153.9 (C2″)，140.5(C3″)，149.2(C5″)，150.4(C6″)，22.5(6″-CH3)，22.1(5″-CH3)， 21.6(3″-CH3).HRMS(ESI)m/z：653.39187[M+Na]+，calcd.for C39H54N2O5630.40327.
EXAMPLE 6 preparation of Compound 4
Weighing 31.2mmol of compound, placing in a 50ml round bottom flask, adding 30ml THF, after the mixture is dissolved, adding 75mg of Pd/C, reducing by hydrogen, stirring at room temperature for 8h, monitoring by TLC that the reaction raw materials are basically disappeared, stopping the reaction, filtering to remove Pd/C, concentrating the reaction solution under reduced pressure, and using 3ml of CHCl for the residue3Redissolving, adding 2.2g of silica gel, evaporating to dryness under reduced pressure, mixing the sample, and eluting with petroleum ether and acetone at a ratio of 5: 1 to obtain 0.673g of white solid. White Amorphous solid, m.p.: 182.8-183.5 ℃ and yield 58.4 percent.1H-NMR(CDCl3)(ppm)：0.69(s，3H，H-18)，0.96(s，3H，H-19)， 0.98(d，J＝6.0Hz，3H，H-21)，4.01(m，1H，H-12)，5.04(m，1H，H-3)，2.73(s， 3H，CH3-6′)，2.57(s，3H，CH3-5′)，2.57(s，3H，CH3-3′)，1.00-2.50(28H， methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.0 (C1)，26.5(C2)，76.2(C3)，32.1(C4)，42.1(C5)，27.0(C6)，26.0(C7)，36.0 (C8)，33.7(C9)，34.2(C10)，28.7(C11)，73.2(C12)，46.5(C13)，48.2(C14)， 23.6(C15)，27.5(C16)，47.3(C17)，12.7(C18)，23.1(C19)，35.1(C20)，17.3 (C21)，31.0(C22)，30.7(C23)，179.0(C24).pyrazine ring：165.6(2′-C＝O)， 154.1(C2′)，140.3(C3′)，149.3(C5′)，150.6(C6′)，22.4(6′-CH3)，22.0 (5′-CH3)，21.4(3′-CH3).HRMS(ESI)m/z：541.36188[M+H]+，calcd.for C32H48N2O5 540.35632.
EXAMPLE 7 preparation of Compound 5
Weighing 2.19mmol of 2-bromomethyl-3, 5, 6-trimethyl pyrazine and 2.19mmol of cholic acid, placing in a 50ml round bottom flask, adding 25ml of DMF, dissolving the mixture, adding 3mmol of potassium carbonate, stirring at 85 ℃ for 2h, monitoring by TLC that the reaction raw materials basically disappear, stopping the reaction, adding a large amount of saturated NaCl solution into the reaction solution for dispersion, extracting twice with 300ml of ethyl acetate, drying the ethyl acetate layer with anhydrous Na2SO4, concentrating under reduced pressure, dissolving the residue with 3ml of chloroform, adding 2.8g of silica gelEvaporating to dryness under reduced pressure, and mixing with eluent petroleum ether and acetone at a ratio of 8: 1 to obtain white solid 0.594 g. m.p.: 95.4-96.3 ℃, yield 55.4%. HRMS (ESI) m/z: 543.6199[ M + H]+，calcd.for C32H51N2O5 543.3798.
EXAMPLE 8 preparation of Compound 6
Weighing 51.2mmol of compound and 1.8mmol of ligustrazine acid, placing in a 50ml round bottom flask, adding 25ml of CH2Cl2After the mixture is dissolved, EDCI 1.8mmol and DMAP 0.18mmol are respectively added, the mixture is stirred for 12h at room temperature, TLC monitors that the reaction raw materials basically disappear, the reaction is stopped, the mixture is concentrated under reduced pressure, 2.2g of silica gel is added, the mixture is evaporated to dryness under reduced pressure and is mixed, and an eluent is petroleum ether and acetone which are 7: 1 to elute, so that 0.396g of white solid is obtained. White Amorphous solid, m.p.: 85.7-86.5 ℃ and yield 47.8 percent.1H-NMR(CDCl3)(ppm)：0.68(s，3H，H-18)，0.93(s，3H，H-19)，0.96(d，J＝ 5.5Hz，3H，H-21)，4.90(m，1H，H-3)，3.87(m，1H，H-7)，3.98(m，1H，H-12)， 5.19(brs，2H，CH2-2′)，2.71(s，3H，CH3-6″)，2.56(s，3H，CH3-5″)，2.56(s，3H， CH3-3″)，2.54(s，3H，CH3-6′)，2.52(s，3H，CH3-5′)，2.51(s，3H，CH3-3′)， 1.00-2.50(26H，methyl-and methylene-of steroid structure).13C-NMR (CDCl3)(ppm)：35.1(C1)，26.7(C2)，76.2(C3)，34.9(C4)，41.3(C5)，34.8 (C6)，68.2(C7)，39.5(C8)，26.6(C9)，34.4(C10)，28.4(C11)，72.9(C12)， 46.5(C13)，42.0(C14)，23.1(C15)，27.4(C16)，47.1(C17)，12.5(C18)，22.5 (C19)，35.2(C20)，17.3(C21)，31.0(C22)，30.8(C23)，173.9(C24)；pyrazine ring：64.9(2′-CH2)，151.2(C2′)，144.9(C3′)，148.9(C5′)，149.1(C6′)，165.8 (2″-C＝O)，153.9(C2″)，140.5(C3″)，149.2(C5″)，150.4(C6″)，21.5(6′-CH3)， 21.4(5′-CH3)，20.4(3′-CH3)，22.6(6″-CH3)，22.1(5″-CH3)，21.6(3″-CH3). HRMS(ESI)m/z：691.44092[M+H]+，calcd.for C40H58N4O6690.43564.
Preparation of intermediate benzyl cholate: weighing benzyl bromide 5.0mmol and cholic acid 5.0mmol, placing in 50ml round bottom flask, adding 25ml DMF, dissolving the mixture, adding 5mmol potassium carbonate, stirring at 85 deg.C for 2 hr, monitoring by TLC that reaction raw materials basically disappear, stopping reaction, adding a large amount of saturated NaCl solution to the reaction solution for dispersion, extracting with 400ml ethyl acetate twice, and using anhydrous Na for ethyl acetate layer2SO4Drying, concentrating under reduced pressure, dissolving the residue with 5ml chloroform, adding 3.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 5: 1 to obtain 2.243g white solid. White powder, m.p.: 177.8-178.6 ℃ and yield 90.1 percent.
EXAMPLE 9 preparation of Compound 7
Weighing 3.0mmol of intermediate benzyl cholic acid and 4.0mmol of ligustrazine acid, placing in a 50ml round bottom flask, adding 30ml CH2Cl2After the mixture is dissolved, respectively adding EDCI 4.0mmol and DMAP 0.4mmol, stirring at room temperature for 12h, monitoring by TLC that the reaction raw material basically disappears, stopping the reaction, washing the reaction solution twice by 60ml of saturated NaCl solution, and obtaining CH2Cl2Anhydrous Na for layer2SO4Drying, concentrating under reduced pressure, adding 3.2g silica gel, evaporating to dryness under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 7: 1 to obtain white solid 0.928 g. White Amorphous solid, m.p.: 169.0-169.6 ℃ and yield 47.9 percent.1H-NMR(CDCl3)(ppm)：0.69(s，3H，H-18)，0.95(s，3H，H-19)，0.98 (d，J＝6.0Hz，3H，H-21)，4.91(m，1H，H-3)，3.88(m，1H，H-7)，4.00(m，1H， H-12)，5.15，5.11(ea，d，J＝12.5Hz，1H，CH2-1′)，7.37(m，5H，H-2′，3′，4′，5′， 6′)，2.72(s，3H，CH3-6″)，2.57(s，3H，CH3-5″)，2.57(s，3H，CH3-3″)， 1.00-2.50(26H，methyl-and methylene-of steroid structure).13C-NMR (CDCl3)(ppm)：35.1(C1)，26.8(C2)，76.2(C3)，34.9(C4)，41.3(C5)，34.8 (C6)，68.2(C7)，39.6(C8)，26.7(C9)，34.4(C10)，28.4(C11)，72.9(C12)， 46.5(C13)，42.0(C14)，23.1(C15)，27.4(C16)，47.2(C17)，12.5(C18)，22.5 (C19)，35.1(C20)，17.3(C21)，31.3(C22)，30.8(C23)，174.0(C24)，66.1 (1′-CH2)，136.1(C1′)，128.2(C2′，6′)，128.5(C3′，5′)，128.2(C4′)；pyrazine ring：165.8(2″-C＝O)，153.9(C2″)，140.6(C3″)，149.3(C5″)，150.4(C6″)， 22.6(6″-CH3)，22.1(5″-CH3)，21.6(3″-CH3).HRMS(ESI)m/z：647.40668 [M+H]+，calcd.for C39H54N2O6 646.39819.
EXAMPLE 10 preparation of Compound 8
Weighing 71.2mmol of compound, placing in 50ml round bottom flask, adding 30ml THF, dissolving the mixture, adding 78mg Pd/C, reducing with hydrogen, stirring at room temperature for 10h, monitoring by TLC that the reaction material is substantially disappeared, stopping the reaction, filtering to remove Pd/C, concentrating the reaction solution under reduced pressure, and adding 3ml CHCl into the residue3Redissolving, adding 2.2g of silica gel, evaporating to dryness under reduced pressure, mixing the sample, and eluting with petroleum ether and acetone at a ratio of 5: 1 to obtain 0.590g of white solid. White Amorphous solid, m.p.: 132.6-133.5 deg.C, yield 88.4%. 1H-NMR (CDCl)3)(ppm)：0.70(s，3H，H-18)，0.93(s，3H，H-19)， 0.98(d，J＝5.5Hz，3H，H-21)，4.89(m，1H，H-3)，3.88(m，1H，H-7)，4.00(m， 1H，H-12)，2.73(s，3H，CH3-6′)，2.57(s，3H，CH3-3′，5′)，1.00-2.50(27H， methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.1 (C1)，26.7(C2)，76.3(C3)，34.9(C4)，41.3(C5)，34.8(C6)，68.3(C7)，39.5 (C8)，26.6(C9)，34.4(C10)，28.3(C11)，73.0(C12)，46.5(C13)，41.9(C14)，23.2(C15)，27.5(C16)，47.0(C17)，12.5(C18)，22.5(C19)，35.2(C20)，17.3 (C21)，30.9(C22)，30.7(C23)，178.3(C24)；pyrazine ring：165.6(2′-C＝O)， 154.0(C2′)，140.3(C3′)，149.2(C5′)，150.6(C6′)，22.5(6′-CH3)，22.0 (5′-CH3)，21.3(3′-CH3).HRMS(ESI)m/z：555.34312[M-H]-，calcd.for C32H48N2O6 556.35124.
EXAMPLE 11 preparation of Compound 9
Weighing 2.19mmol of 2-bromomethyl-3, 5, 6-trimethylpyrazine and 2.19mmol of hyodeoxycholic acid, placing the mixture in a 50ml round-bottom flask, adding 25ml of DMF, adding 3mmol of potassium carbonate after the mixture is dissolved, stirring at 85 ℃ for 2h, monitoring by TLC that reaction raw materials basically disappear, stopping reaction, adding a large amount of saturated NaCl solution into a reaction solution for dispersion, extracting by 300ml of ethyl acetate twice, and using anhydrous Na for an ethyl acetate layer2SO4Drying, concentrating under reduced pressure, dissolving the residue with 3ml chloroform, adding 2.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 8: 1 to obtain white solid 0.594 g. m.p.: 65.3-66.1 deg.C, yield 51.6%. 1H-NMR (CDCl)3)(ppm)：0.62(s，3H， H-18)，0.90(s，3H，H-19)，0.91(d，J＝6.0Hz，3H，H-21)，3.61(m，1H，H-3)， 4.05(m，1H，H-6)，5.19(t，J＝12.5Hz，2H，CH2-2′)，2.53(s，3H，CH3-6′)， 2.51(s，3H，CH3-5′)，2.51(s，3H，CH3-3′)，1.00-2.50(28H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.6(C1)，29.2 (C2)，71.5(C3)，28.1(C4)，48.5(C5)，68.0(C6)，35.0(C7)，34.8(C8)，39.8 (C9)，35.9(C10)，20.7(C11)，39.9(C12)，42.8(C13)，56.1(C14)，24.2(C15)， 30.2(C16)，55.9(C17)，12.0(C18)，23.5(C19)，35.3(C20)，18.2(C21)，31.1 (C22)，30.9(C23)，173.9(C24)；pyrazine ring：64.9(2′-CH2)，151.2(C2′)， 144.9(C3′)，149.0(C5′)，149.0(C6′)，21.6(6′-CH3)，21.4(5′-CH3)，20.5 (3′-CH3).HRMS(ESI)m/z：527.38214[M+H]+，calcd.for C32H50N2O4 526.37706.
EXAMPLE 12 preparation of Compound 10
Weighing about 1.2mmol of compound 9 and 1.8mmol of ligustrazine acid, placing in a 50ml round bottom flask, adding 25ml of CH2Cl2After the mixture is dissolved, respectively adding EDCI 1.8mmol and DMAP 0.18mmol, stirring at room temperature for 12h, monitoring by TLC that the reaction raw material basically disappears, stopping the reaction, concentrating under reduced pressure, adding 2.2g of silica gel, evaporating to dryness under reduced pressure, mixing with a sample, and eluting with petroleum ether and acetone which are 8: 1, and a white semisolid which is 0.181 g.m.p.: 72.3-73.1 deg.C, yield 18.4%. 1H-NMR (CDCl)3) (ppm)：0.67(s，3H，H-18)，1.01(s，3H，H-19)，0.92(d，J＝6.5Hz，3H，H-21)， 5.04(m，1H，H-3)，5.51(m，1H，H-6)，5.20(t，J＝12.5Hz，2H，CH2-2′)， 2.48-2.71(s，each，3H，9×CH3-pyrazine ring)，1.00-2.50(25H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.3(C1)，26.5 (C2)，75.5(C3)，26.4(C4)，45.6(C5)，72.9(C6)，31.3(C7)，34.8(C8)，39.9 (C9)，36.3(C10)，20.7(C11)，39.9(C12)，42.9(C13)，56.1(C14)，24.1(C15)， 28.1(C16)，55.9(C17)，12.0(C18)，23.3(C19)，35.1(C20)，18.2(C21)，31.1 (C22)，30.9(C23)，173.8(C24)；pyrazine ring：65.0(2′-CH2)，151.2(C2′)， 144.9(C3′)，149.0(C5′)，149.0(C6′)，165.5(2″-C＝O)，154.1(C2″)，140.4 (C3″)，149.3(C5″)，150.2(C6″)，165.7(2″′-C＝O)，154.0(C2″′)，140.3(C3″′)， 149.2(C5″′)，150.5(C6″)，21.6(6′-CH3)，21.5(5′-CH3)，20.5(3′-CH3)，22.6 (6″-CH3)，22.1(5″-CH3)，21.7(3″-CH3)，22.5(6″′-CH3)，22.1(5″′-CH3)，21.6 (3″′-CH3).HRMS(ESI)m/z：823.51044[M+H]+，calcd.for C48H66N6O6 822.50438.
EXAMPLE 13 preparation of Compound 11
This structure was isolated in the preparation of compound 10 as a white semi-solid, 0.149 g. Semi solid, yield 22.1%. 1H-NMR (CDCl)3)(ppm)：0.66(s，3H，H-18)，1.04(s， 3H，H-19)，0.92(d，J＝6.5Hz，3H，H-21)，3.61(m，1H，H-3)，5.47(m，1H， H-6)，5.20(t，J＝12.5Hz，2H，CH2-2′)，2.71(s，3H，CH3-6″)，2.56(brs，6H， CH3-3″，5″)，2.54(s，3H，CH3-6′)，2.52(s，3H，CH3-5′)，2.52(s，3H，CH3-3′)， 1.00-2.50(27H，methyl-and methylene-of steroid structure).13C-NMR (CDCl3)(ppm)：35.4(C1)，30.2(C2)，71.2(C3)，28.1(C4)，45.5(C5)，73.3 (C6)，31.3(C7)，34.8(C8)，39.9(C9)，36.2(C10)，20.7(C11)，39.9(C12)， 42.9(C13)，56.1(C14)，24.1(C15)，30.3(C16)，55.9(C17)，12.0(C18)，23.3 (C19)，35.3(C20)，18.2(C21)，31.1(C22)，30.9(C23)，173.8(C24)；pyrazine ring：64.9(2′-CH2)，151.2(C2′)，144.9(C3′)，149.0(C5′)，149.0(C6′)，165.7 (2″-C＝O)，154.0(C2″)，140.4(C3″)，149.3(C5″)，150.2(C6″)，21.6(6′-CH3)， 21.4(5′-CH3)，20.5(3′-CH3)，22.5(6″-CH3)，22.1(5″-CH3)，21.6(3″-CH3). HRMS(ESI)m/z：675.44873[M+H]+，calcd.for C40H58N4O5 674.44072.
Preparation of hyodeoxycholic acid benzyl ester: placing benzyl bromide 5.0mmol and hyodeoxycholic acid 5.0mmol in 50ml round bottom flask, adding 25ml DMF, dissolving the mixture, adding 5mmol potassium carbonate, stirring at 85 deg.C for 2 hr, monitoring by TLC that reaction raw materials basically disappear, stopping reaction, adding a large amount of saturated NaCl solution to the reaction solution for dispersion, extracting with 400ml ethyl acetate twice, and using anhydrous Na for ethyl acetate layer2SO4Drying, concentrating under reduced pressure, dissolving the residue with 5ml chloroform, adding 3.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 5: 1 to obtain white solid 2.234 g. White powder, m.p.: 132.4-133.3 ℃ and yield 92.7 percent.
EXAMPLE 14 preparation of Compound 12
3.0mmol of hyodeoxycholic acid benzyl ester and 4.0mmol of ligustrazine acid are weighed and placed in a 50ml round bottom flask, and 30ml of CH is added2Cl2After the mixture is dissolved, respectively adding EDCI 4.0mmol and DMAP 0.4mmol, stirring at room temperature for 12h, monitoring by TLC that the reaction raw material basically disappears, stopping the reaction, washing the reaction solution twice by 60ml of saturated NaCl solution, and obtaining CH2Cl2Anhydrous Na for layer2SO4Drying, concentrating under reduced pressure, adding 3.2g silica gel, evaporating to dryness under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 7: 1 to obtain white solid 0.391 g. M.p.: 55.3-56.1 deg.C, yield 20.7%. 1H-NMR (CDCl)3) (ppm)：0.66(s，3H，H-18)，1.04(s，3H，H-19)，0.92(d，J＝6.5Hz，3H，H-21)， 3.64(m，1H，H-3)，5.48(m，1H，H-6)，5.14，5.11(ea，d，J＝12.5Hz，1H， CH2-1′)，7.37(m，5H，H-2′，3′，4′，5′，6′)，2.71(s，3H，CH3-6″)，2.57(brs，6H， CH3-3″，5″)，1.00-2.50(26H，methyl-and methylene-of steroid structure). 13C-NMR(CDCl3)(ppm)：35.4(C1)，30.2(C2)，71.2(C3)，28.1(C4)，45.5 (C5)，73.3(C6)，31.3(C7)，34.8(C8)，39.9(C9)，36.2(C10)，20.7(C11)，39.9 (C12)，42.9(C13)，56.1(C14)，24.2(C15)，30.2(C16)，55.9(C17)，12.0 (C18)，23.4(C19)，35.3(C20)，18.2(C21)，31.0(C22)，30.9(C23)，174.1 (C24)，66.1(1′-CH2)，136.1(C1′)，128.3(C2′，6′)，128.6(C3′，5′)，128.2(C4′)； pyrazine ring：165.7(2″-C＝O)，154.0(C2″)，140.4(C3″)，149.4(C5″)，150.2 (C6″)，22.6(6″-CH3)，22.1(5″-CH3)，21.7(3″-CH3).HRMS(ESI)m/z：631.40991[M+H]+，calcd.for C39H54N2O5 630.40327.
EXAMPLE 15 preparation of Compound 13
This structure was isolated in the preparation of compound 12 as a white solid, 0.448 g.m.p.: 61.3-62.1 deg.C, yield 19.2%. 1H-NMR (CDCl)3)(ppm)：0.66(s，3H，H-18)， 1.09(s，3H，H-19)，0.92(d，J＝6.5Hz，3H，H-21)，5.04(m，1H，H-3)，5.50(m， 1H，H-6)，5.14，5.11(ea，d，J＝12.0Hz，2H，CH2-1′)，7.37(m，5H，H-2′，3′，4′， 5′，6′)，2.55-2.72(s，each，3H，6×CH3-pyrazine ring)，1.00-2.50(26H， methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.3 (C1)，26.5(C2)，75.6(C3)，26.4(C4)，45.6(C5)，72.9(C6)，31.3(C7)，34.8 (C8)，39.8(C9)，36.3(C10)，20.7(C11)，39.9(C12)，42.9(C13)，56.1(C14)， 24.2(C15)，28.1(C16)，55.9(C17)，12.0(C18)，23.3(C19)，35.1(C20)，18.3 (C21)，31.0(C22)，30.9(C23)，174.0(C24)，66.1(1′-CH2)，136.1(C1′)，128.3 (C2′，6′)，128.6(C3′，5′)，128.2(C4′)；pyrazine ring：165.7(2″-C＝O)，154.1 (C2″)，140.4(C3″)，149.3(C5″)，150.6(C6″)，165.6(2″′-C＝O)，154.1(C2″′)， 140.3(C3″′)，149.3(C5″′)，150.2(C6″)，22.6(6″-CH3)，22.2(5″-CH3)，21.7 (3″-CH3)，22.5(6″′-CH3)，22.1(5″′-CH3)，21.6(3″′-CH3).HRMS(ESI)m/z： 779.47357[M+H]+，calcd.for C47H62N4O6 778.46694.
EXAMPLE 16 preparation of Compound 14
Weighing about 0.3mmol of compound 12, placing in 50ml round bottom flask, adding 30ml THF, dissolving the mixture, adding Pd/C40 mg, reducing with hydrogen, stirring at room temperature for 10 hr, TLC monitoring reaction material disappearance, stopping reaction, filtering to remove Pd/C, concentrating the reaction solution under reduced pressure, and collecting the residue with 3ml CHCl3Redissolving, adding 2.2g of silica gel, evaporating to dryness under reduced pressure, mixing the sample, and eluting with petroleum ether and acetone at a ratio of 5: 1 to obtain a white solid of 0.147 g.m.p.: 39.1-39.9 deg.C, yield 90.6%. 1H-NMR (CDCl)3)(ppm)：0.69(s，3H，H-18)，1.05(s，3H，H-19)，0.95(d，J＝6.5Hz， 3H，H-21)，3.64(m，1H，H-3)，5.48(m，1H，H-6)，2.72(s，3H，CH3-6″)，2.57 (brs，6H，CH3-3″，5″)，1.00-2.50(28H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.4(C1)，30.1(C2)，71.3(C3)，28.1 (C4)，45.5(C5)，73.4(C6)，31.3(C7)，34.8(C8)，39.9(C9)，36.2(C10)，20.7 (C11)，39.9(C12)，43.0(C13)，56.0(C14)，24.2(C15)，30.2(C16)，56.0 (C17)，12.1(C18)，23.3(C19)，35.4(C20)，18.3(C21)，31.0(C22)，30.8 (C23)，178.8(C24)；pyrazine ring：165.6(2′-C＝O)，154.1(C2′)，140.3(C3′)， 149.3(C5′)，150.4(C6′)，22.5(6′-CH3)，22.1(5′-CH3)，21.5(3′-CH3).HRMS (ESI)m/z：541.36359[M+H]+，calcd.for C32H48N2O5 540.35632.
EXAMPLE 17 preparation of Compound 15
Weighing compound 13 about 0.3mmol, placing in 50ml round bottom flask, adding THF 30ml, dissolving the mixture, adding Pd/C40 mg, reducing with hydrogen, stirring at room temperature for 10 hr, TLC monitoring reaction raw material disappearance, stopping reaction, filtering to remove Pd/C, concentrating the reaction solution under reduced pressure, and collecting residue with 3ml CHCl3Redissolving, adding 2.2g of silica gel, evaporating to dryness under reduced pressure, mixing the sample, and eluting with petroleum ether and acetone at a ratio of 5: 1 to obtain 0.147g of white solid. m.p.: 88.3-89.0 ℃, yield 91.5%. 1H-NMR (CDCl)3)(ppm)：0.70(s，3H，H-18)，1.09(s，3H，H-19)，0.95(d，J＝6.5Hz， 3H，H-21)，5.04(m，1H，H-3)，5.51(m，1H，H-6)，2.55-2.73(s，each，3H， 6×CH3-pyrazine ring)，1.00-2.50(27H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.3(C1)，26.4(C2)，75.6(C3)，26.4 (C4)，45.6(C5)，73.0(C6)，31.3(C7)，34.8(C8)，39.9(C9)，36.3(C10)，20.7 (C11)，40.0(C12)，43.0(C13)，56.2(C14)，24.2(C15)，28.1(C16)，56.0 (C17)，12.0(C18)，23.3(C19)，35.2(C20)，18.3(C21)，31.0(C22)，30.8 (C23)，178.7(C24)；pyrazine ring：165.6(2′-C＝O)，154.1(C2′)，140.3(C3′)， 149.3(C5′)，150.6(C6′)，165.5(2″-C＝O)，154.1(C2″)，140.3(C3″)，149.3 (C5″)，150.3(C6′)，22.5(6′-CH3)，22.1(5′-CH3)，21.5(3′-CH3)，22.4(6″-CH3)， 22.0(5″-CH3)，21.5(3″-CH3).HRMS(ESI)m/z：689.42712[M+H]+，calcd. for C40H56N4O6 688.41999.
EXAMPLE 18 preparation of Compound 16
Weighing 2.19mmol of 2-bromomethyl-3, 5, 6-trimethyl pyrazine and ursodesoxyPlacing cholic acid 2.19mmol in 50ml round bottom flask, adding 25ml DMF, dissolving the mixture, adding 3mmol potassium carbonate, stirring at 85 deg.C for 2 hr, TLC monitoring reaction raw material disappearance, stopping reaction, dispersing the reaction solution with large amount of saturated NaCl solution, extracting with 300ml ethyl acetate twice, separating ethyl acetate layer with anhydrous Na2SO4Drying, concentrating under reduced pressure, dissolving the residue with 3ml chloroform, adding 2.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 8: 1 to obtain white solid 0.596 g. m.p.: 46.2-46.9 ℃, yield 51.7%. 1H-NMR (CDCl)3)(ppm)：0.65(s，3H， H-18)，0.94(s，3H，H-19)，0.91(d，J＝6.0Hz，3H，H-21)，3.58(brs，2H，H-3， 7)，5.19(t，J＝12.5Hz，2H，CH2-2′)，2.52(s，3H，CH3-6′)，2.51(s，3H， CH3-5′)，2.50(s，3H，CH3-3′)，1.00-2.50(28H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.0(C1)，30.3(C2)，71.33 (C3)，37.3(C4)，42.5(C5)，36.9(C6)，71.29(C7)，43.7(C8)，39.2(C9)，34.1 (C10)，21.2(C11)，40.1(C12)，43.8(C13)，55.8(C14)，26.9(C15)，28.6 (C16)，54.9(C17)，12.1(C18)，23.4(C19)，35.2(C20)，18.4(C21)，31.1 (C22)，31.0(C23)，173.8(C24)；pyrazine ring：64.9(2′-CH2)，151.2(C2′)， 144.9(C3′)，149.0(C5′)，149.0(C6′)，21.6(6′-CH3)，21.4(5′-CH3)，20.4 (3′-CH3).HRMS(ESI)m/z：527.38373[M+H]+，calcd.for C32H50N2O4 526.37706.
EXAMPLE 19 preparation of Compound 17
Weighing about 1.2mmol of compound 16 and 1.8mmol of ligustrazine acid, placing in a 50ml round bottom flask, adding 25ml of CH2Cl2After the mixture is dissolved, respectively adding EDCI 1.8mmol and DMAP 0.18mmol, stirring at room temperature for 12h, monitoring the reaction raw material by TLC to basically disappear, stopping the reaction, concentrating under reduced pressure,adding 2.2g of silica gel, evaporating to dryness under reduced pressure, mixing the mixture with a sample, and eluting with petroleum ether and acetone at a ratio of 8: 1 to obtain 0.231g of white solid respectively. White Amorphous solid, m.p.: 59.1-59.9 deg.C, yield 28.6%. 1H-NMR (CDCl)3)(ppm)：0.68(s，3H，H-18)，1.00(s，3H，H-19)，0.92 (d，J＝6.0Hz，3H，H-21)，5.00(m，1H，H-3)，3.60(m，1H，H-7)，5.20(t，J＝ 12.5Hz，2H，CH2-2′)，2.72(s，3H，CH3-6″)，2.58(s，3H，CH3-5″)，2.57(s，3H， CH3-3″)，2.54(s，3H，CH3-6′)，2.52(s，3H，CH3-5′)，2.51(s，3H，CH3-3′)， 1.00-2.50(27H，methyl-and methylene-of steroid structure).13C-NMR (CDCl3)(ppm)：34.7(C1)，26.5(C2)，75.7(C3)，33.1(C4)，42.4(C5)，36.7 (C6)，71.2(C7)，43.7(C8)，39.1(C9)，34.2(C10)，21.5(C11)，40.1(C12)， 43.7(C13)，55.7(C14)，26.9(C15)，28.6(C16)，54.9(C17)，12.1(C18)，23.3 (C19)，35.2(C20)，18.4(C21)，31.1(C22)，31.0(C23)，173.9(C24)；pyrazine ring：65.0(2′-CH2)，151.2(C2′)，144.9(C3′)，149.0(C5′)，149.0(C6′)，165.7 (2″-C＝O)，154.1(C2″)，140.3(C3″)，149.3(C5″)，150.6(C6″)，21.5(6′-CH3)， 21.2(5′-CH3)，20.5(3′-CH3)，22.6(6″-CH3)，22.1(5″-CH3)，21.7(3″-CH3). HRMS(ESI)m/z：675.44788[M+H]+，calcd.for C40H58N4O5674.44072.
EXAMPLE 20 preparation of Compound 18
This structure was isolated in the preparation of compound 17 as a colorless oil, 0.155 g. yield 15.7%. 1H-NMR (CDCl)3)(ppm)：0.68(s，3H，H-18)，1.01(s，3H，H-19)，0.91 (d，J＝6.5Hz，3H，H-21)，5.02(m，1H，H-3)，5.11(m，1H，H-7)，5.17(t，J＝ 12.5Hz，2H，CH2-2′)，2.48-2.71(s，each，3H，9×CH3-pyrazine ring)， 1.00-2.50(26H，methyl-and methylene-of steroid structure).13C-NMR (CDCl3)(ppm)：34.6(C1)，26.4(C2)，75.5(C3)，32.8(C4)，40.0(C5)，32.9 (C6)，75.4(C7)，42.4(C8)，39.6(C9)，34.2(C10)，21.6(C11)，39.9(C12)， 43.6(C13)，55.3(C14)，25.9(C15)，28.4(C16)，55.0(C17)，12.1(C18)，23.3 (C19)，35.2(C20)，18.3(C21)，31.0(C22)，30.9(C23)，173.8(C24)；pyrazine ring：64.9(2′-CH2)，151.2(C2′)，144.9(C3′)，148.9(C5′)，149.0(C6′)，165.7 (2″-C＝O)，154.1(C2″)，140.2(C3″)，149.3(C5″)，150.6(C6″)，165.7 (2″′-C＝O)，153.9(C2″′)，140.2(C3″′)，149.2(C5″′)，150.7(C6″)，21.4 (6′-CH3)，21.3(5′-CH3)，20.5(3′-CH3)，22.6(6″-CH3)，22.1(5″-CH3)，21.7 (3″-CH3)，22.6(6″′-CH3)，22.2(5″′-CH3)，21.6(3″′-CH3).HRMS(ESI)m/z： 823.51196[M+H]+，calcd.for C48H66N6O6 822.50438.
Preparation of ursodeoxycholic acid benzyl ester: weighing benzyl bromide 5.0mmol and ursodeoxycholic acid 5.0mmol, placing in 50ml round bottom flask, adding DMF 25ml, dissolving the mixture, adding potassium carbonate 5mmol, stirring at 85 deg.C for 2 hr, monitoring by TLC that the reaction raw materials basically disappear, stopping reaction, adding a large amount of saturated NaCl solution into the reaction solution for dispersion, extracting with ethyl acetate 400ml twice, and using anhydrous Na for ethyl acetate layer2SO4Drying, concentrating under reduced pressure, dissolving the residue with 5ml chloroform, adding 3.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 5: 1 to obtain 2.181g white solid. White powder, m.p.: 142.5-143.2 ℃ and yield 90.5 percent.
EXAMPLE 21 preparation of Compound 19
Weighing 3.0mmol of ursodeoxycholic acid benzyl ester and 4.0mmol of ligustrazine acid, placing in a 50ml round bottom flask, adding 30ml of CH2Cl2After the mixture is dissolved, respectively adding EDCI 4.0mmol and DMAP 0.4mmol, stirring at room temperature for 12h, monitoring by TLC that the reaction raw material basically disappears, stopping the reaction, washing the reaction solution twice by 60ml of saturated NaCl solution, and obtaining CH2Cl2Anhydrous Na for layer2SO4Drying, concentrating under reduced pressure, adding 3.2g silica gel, evaporating to dryness under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 7: 1 to obtain white solid 0.486 g. White Amorphous solid, m.p.: 58.4-59.2 deg.C, yield 25.7%. 1H-NMR (CDCl)3)(ppm)：0.68(s，3H，H-18)，1.00(s，3H，H-19)，0.93(d，J＝ 6.5Hz，3H，H-21)，5.00(m，1H，H-3)，3.61(m，1H，H-7)，5.14，5.11(ea，d，J ＝12.0Hz，1H，CH2-1′)，7.37(m，5H，H-2′，3′，4′，5′，6′)，2.73(s，3H，CH3-6″)， 2.58(s，3H，CH3-5″)，2.57(s，3H，CH3-3″)，1.00-2.50(27H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：34.7(C1)，26.5 (C2)，75.7(C3)，33.1(C4)，42.5(C5)，36.7(C6)，71.2(C7)，43.8(C8)，39.2 (C9)，34.2(C10)，21.2(C11)，40.1(C12)，43.8(C13)，55.7(C14)，26.9(C15)， 28.6(C16)，55.0(C17)，12.1(C18)，23.3(C19)，35.2(C20)，18.4(C21)，31.3 (C22)，31.0(C23)，174.0(C24)，66.1(1′-CH2)，136.1(C1′)，128.2(C2′，6′)， 128.5(C3′，5′)，128.2(C4′)；pyrazine ring：165.7(2″-C＝O)，154.1(C2″)， 140.3(C3″)，149.2(C5″)，150.5(C6″)，22.5(6″-CH3)，22.1(5″-CH3)，21.6 (3″-CH3).HRMS(ESI)m/z：631.41046[M+H]+，calcd.for C39H54N2O5630.40327.
EXAMPLE 22 preparation of Compound 20
This structure was isolated in the preparation of compound 19, 0.334 g. White solid, m.p.: 147.2-148.0 deg.C, yield 14.3%. 1H-NMR (CDCl)3)(ppm)：0.68(s，3H，H-18)， 1.07(s，3H，H-19)，0.91(d，J＝6.0Hz，3H，H-21)，5.02(m，2H，H-3，7)，5.10 (brs，2H，CH2-1′)，7.37(m，5H，H-2′，3′，4′，5′，6′)，2.56-2.75(s，each，3H， 6×CH3-pyrazine ring)，1.00-2.50(26H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：34.7(C1)，26.5(C2)，75.5(C3)，32.9 (C4)，40.1(C5)，32.9(C6)，75.3(C7)，42.4(C8)，39.7(C9)，34.2(C10)，21.3 (C11)，40.0(C12)，43.7(C13)，55.4(C14)，25.9(C15)，28.3(C16)，55.1 (C17)，12.1(C18)，23.3(C19)，35.1(C20)，18.4(C21)，31.3(C22)，31.0 (C23)，173.9(C24)，66.0(1′-CH2)，136.2(C1′)，128.1(C2′，6′)，128.5(C3′，5′)， 128.1(C4′)；pyrazine ring：165.7(2″-C＝O)，153.9(C2″)，140.3(C3″)，149.1 (C5″)，150.5(C6″)，165.7(2″′-C＝O)，153.7(C2″′)，140.3(C3″′)，149.1(C5″′)， 150.5(C6″)，22.4(6″-CH3)，22.0(5″-CH3)，21.5(3″-CH3)，22.4(6″′-CH3)， 22.0(5″′-CH3)，21.5(3″′-CH3).HRMS(ESI)m/z：779.47418[M+H]+，calcd. for C47H62N4O6 778.46694.
EXAMPLE 23 preparation of Compound 21
Weighing about 0.6mmol of compound 19, placing in a 50ml round-bottom flask, adding 30ml THF, adding Pd (OH) after the mixture is dissolved240mg of/C, hydrogen reduction, stirring at room temperature for 10 hours, monitoring by TLC that the reaction material is substantially disappeared, stopping the reaction, filtering to remove Pd (OH)2C, concentrating the reaction solution under reduced pressure, and adding 3ml of CHCl into the residue3Redissolving, adding 2.2g of silica gel, evaporating to dryness under reduced pressure, mixing the sample, and eluting with petroleum ether and acetone at a ratio of 5: 1 to obtain 0.301g of white solid. White Amorphous solid, m.p.: 101.9-102.7 ℃, yield 92.8%. 1H-NMR (CDCl)3)(ppm)：0.71(s，3H，H-18)， 1.01(s，3H，H-19)，0.96(d，J＝6.5Hz，3H，H-21)，5.01(m，1H，H-3)，3.62(m， 1H，H-7)，2.73(s，3H，CH3-6′)，2.58(s，3H，CH3-5′)，2.58(s，3H，CH3-3′)， 1.00-2.50(28H，methyl-and methylene-of steroid structure).13C-NMR (CDCl3)(ppm)：34.7(C1)，26.5(C2)，75.7(C3)，33.1(C4)，42.4(C5)，36.7 (C6)，71.3(C7)，43.7(C8)，39.2(C9)，34.2(C10)，21.2(C11)，40.1(C12)， 43.8(C13)，55.7(C14)，26.9(C15)，28.6(C16)，55.0(C17)，12.1(C18)，23.3 (C19)，35.2(C20)，18.4(C21)，31.0(C22)，30.8(C23)，178.9(C24)；pyrazine ring：165.6(2′-C＝O)，154.2(C2′)，140.3(C3′)，149.3(C5″)，150.6(C6′)，22.5 (6′-CH3)，22.1(5′-CH3)，21.6(3′-CH3).HRMS(ESI)m/z：541.36322[M+H]+， calcd.for C32H48N2O5 540.35632.
EXAMPLE 24 preparation of Compound 22
Weighing about 0.3mmol of compound 20, placing in a 50ml round bottom flask, adding 30ml THF, adding Pd (OH) after the mixture is dissolved225 mg/C, hydrogen reduction, stirring at room temperature for 10h, monitoring by TLC that the reaction material is substantially disappeared, stopping the reaction, filtering to remove Pd (OH)2C, concentrating the reaction solution under reduced pressure, and adding 3ml of CHCl into the residue3Redissolving, adding 2.2g silica gel, drying by distillation under reduced pressure, mixing the sample, and eluting with petroleum ether and acetone at a ratio of 5: 1 to obtain 0.193g white solid. m.p.: 147.2-148.0 deg.C, yield 93.4%. 1H-NMR (CDCl)3)(ppm)：0.71(s，3H，H-18)，1.07(s，3H，H-19)，0.93 (d，J＝6.0Hz，3H，H-21)，5.02(m，1H，H-3)，5.12(m，1H，H-7)，2.57-2.80(s， each，3H，6×CH3-pyrazine ring)，1.00-2.50(27H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：34.6(C1)，26.4(C2)，75.5(C3)， 32.8(C4)，40.0(C5)，32.9(C6)，75.4(C7)，42.4(C8)，39.6(C9)，34.2(C10)， 21.3(C11)，39.9(C12)，43.7(C13)，55.4(C14)，25.9(C15)，28.4(C16)，55.0 (C17)，12.1(C18)，23.3(C19)，35.2(C20)，18.3(C21)，30.8(C22)，30.9 (C23)，178.6(C24)；pyrazine ring：165.6(2′-C＝O)，154.1(C2′)，140.2(C3′)， 149.3(C5′)，150.6(C6′)，165.6(2″-C＝O)，153.9(C2″)，140.2(C3″)，149.2 (C5″)，150.6(C6′)，22.5(6′-CH3)，22.0(5′-CH3)，21.5(3′-CH3)，22.4(6″-CH3)， 22.0(5″-CH3)，21.5(3″-CH3).HRMS(ESI)m/z：689.42834[M+H]+，calcd. for C40H56N4O6 688.41999.
EXAMPLE 25 preparation of Compound 23
Weighing 2.19mmol of 2-bromomethyl-3, 5, 6-trimethylpyrazine and 2.19mmol of chenodeoxycholic acid, placing the materials in a 50ml round-bottom flask, adding 25ml of DMF, adding 3mmol of potassium carbonate after the mixture is dissolved, stirring for 2h at 85 ℃, monitoring the basic disappearance of reaction raw materials by TLC, stopping the reaction, adding a large amount of saturated NaCl solution into the reaction solution for dispersion, extracting twice by 300ml of ethyl acetate, and using anhydrous Na for an ethyl acetate layer2SO4Drying, concentrating under reduced pressure, dissolving the residue with 3ml chloroform, adding 2.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 8: 1 to obtain white solid 0.638 g. m.p.: 64.8-64.6 ℃, yield 55.4%. 1H-NMR (CDCl)3)(ppm)：0.64(s，3H， H-18)，0.90(s，3H，H-19)，0.91(d，J＝6.5Hz，3H，H-21)，3.44(m，1H，H-3)， 3.84(brs，1H，H-7)，5.19(t，J＝12.5Hz，2H，CH2-2′)，2.53(s，3H，CH3-6′)， 2.51(s，3H，CH3-5′)，2.50(s，3H，CH3-3′)，1.00-2.50(28H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.3(C1)，30.7 (C2)，71.9(C3)，39.8(C4)，41.5(C5)，34.7(C6)，68.3(C7)，39.6(C8)，32.8 (C9)，35.0(C10)，20.6(C11)，39.4(C12)，42.6(C13)，50.4(C14)，23.6(C15)， 28.1(C16)，55.8(C17)，11.7(C18)，22.8(C19)，35.4(C20)，18.2(C21)，31.0 (C22)，31.0(C23)，173.9(C24)；pyrazine ring：64.9(2′-CH2)，151.2(C2′)， 144.9(C3′)，148.9(C5′)，149.0(C6′)，21.6(6′-CH3)，21.4(5′-CH3)，20.5 (3′-CH3).HRMS(ESI)m/z：527.38440[M+H]+，calcd.for C32H50N2O4526.37706.
EXAMPLE 26 preparation of Compound 24
Weighing about 1.2mmol of compound 23 and 1.8mmol of ligustrazine acid, placing in a 50ml round bottom flask, adding 25ml of CH2Cl2After the mixture is dissolved, EDCI 1.8mmol and DMAP 0.18mmol are respectively added, the mixture is stirred for 12h at room temperature, TLC monitors that the reaction raw materials basically disappear, the reaction is stopped, the mixture is concentrated under reduced pressure, 2.2g of silica gel is added, the mixture is evaporated to dryness under reduced pressure and is mixed, and eluent is petroleum ether and acetone which are 7: 1 to elute, so that 0.373g of white oily matter is obtained. Oil, yield 46.1%. 1H-NMR (CDCl)3)(ppm)：0.66(s， 3H，H-18)，0.95(s，3H，H-19)，0.92(d，J＝6.0Hz，3H，H-21)，4.91(m，1H， H-3)，3.87(brs，1H，H-7)，5.19(t，J＝12.5Hz，2H，CH2-2′)，2.71(s，3H， CH3-6″)，2.56(s，3H，CH3-5″)，2.55(s，3H，CH3-3″)，2.53(s，3H，CH3-6′)，2.51(s，3H，CH3-5′)，2.51(s，3H，CH3-3′)，1.00-2.50(27H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.2(C1)，26.7 (C2)，76.3(C3)，35.4(C4)，41.4(C5)，34.5(C6)，68.4(C7)，39.6(C8)，32.8 (C9)，35.1(C10)，20.6(C11)，39.4(C12)，42.7(C13)，50.4(C14)，23.7(C15)， 28.1(C16)，55.8(C17)，11.8(C18)，22.7(C19)，35.3(C20)，18.2(C21)，31.0 (C22)，31.0(C23)，173.9(C24)；pyrazine ring：64.9(2′-CH2)，151.2(C2′)， 144.9(C3′)，149.0(C5′)，149.0(C6′)，165.8(2″-C＝O)，153.9(C2″)，140.5 (C3″)，149.2(C5″)，150.4(C6″)，21.5(6′-CH3)，21.4(5′-CH3)，20.5(3′-CH3)，22.6(6″-CH3)，22.1(5″-CH3)，21.6(3″-CH3).HRMS(ESI)m/z：675.44879 [M+H]+，calcd.for C40H58N4O5 674.44072.
Preparing chenodeoxycholic acid benzyl ester: weighing benzyl bromide 5.0mmol and chenodeoxycholic acid 5.0mmol, placing in 50ml round bottom flask, adding 25ml DMF, dissolving the mixture, adding 5mmol potassium carbonate, stirring at 85 deg.C for 2h, monitoring by TLC that the reaction raw materials basically disappear, stopping the reaction, adding a large amount of saturated NaCl solution into the reaction solution for dispersion, extracting twice with 400ml ethyl acetate, using anhydrous Na for ethyl acetate layer2SO4Drying, concentrating under reduced pressure, dissolving the residue with 5ml chloroform, adding 3.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 5: 1 to obtain white solid 2.157 g. White powder, m.p.: 146.9-147.7 ℃ and yield 89.5 percent.
EXAMPLE 27 preparation of Compound 25
3.0mmol of chenodeoxycholic acid benzyl ester and 4.0mmol of ligustrazine acid are weighed and placed in a 50ml round-bottom flask, and 30ml of CH is added2Cl2After the mixture is dissolved, respectively adding EDCI 4.0mmol and DMAP 0.4mmol, stirring at room temperature for 12h, monitoring by TLC that the reaction raw material basically disappears, stopping the reaction, washing the reaction solution twice by 60ml of saturated NaCl solution, and obtaining CH2Cl2Anhydrous Na for layer2SO4, concentrating under reduced pressure, adding 3.2g silica gel, evaporating to dryness under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 7: 1 to obtain white solid 0.911 g. m.p.: 64.8-64.6 ℃, yield 48.2%. 1H-NMR (CDCl)3) (ppm)：0.65(s，3H，H-18)，0.96(s，3H，H-19)，0.92(d，J＝6.0Hz，3H，H-21)， 4.92(m，1H，H-3)，3.87(brs，1H，H-7)，5.14，5.10(ea，d，J＝12.5Hz，1H， CH2-1′)，7.36(m，5H，H-2′，3′，4′，5′，6′)，2.72(s，3H，CH3-6″)，2.56(s，3H，CH3-5″)，2.56(s，3H，CH3-3″)，1.00-2.50(27H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.2(C1)，26.8(C2)，76.3(C3)， 35.2(C4)，41.4(C5)，34.5(C6)，68.4(C7)，39.6(C8)，32.8(C9)，35.1(C10)， 20.6(C11)，39.4(C12)，42.7(C13)，50.4(C14)，23.7(C15)，28.1(C16)，55.8 (C17)，11.8(C18)，22.7(C19)，35.3(C20)，18.3(C21)，31.3(C22)，31.0 (C23)，174.0(C24)，66.1(1′-CH2)，136.1(C1′)，128.2(C2′，6′)，128.5(C3′，5′)， 128.1(C4′)；pyrazine ring：165.8(2″-C＝O)，153.8(C2″)，140.6(C3″)，149.2 (C5″)，150.3(C6″)，22.5(6″-CH3)，22.1(5″-CH3)，21.5(3″-CH3).HRMS(ESI) m/z：631.40985[M+H]+，calcd.for C39H54N2O5 630.40327.
EXAMPLE 28 preparation of Compound 26
Weighing compound 25 about 1.2mmol, placing in 50ml round bottom flask, adding THF 30ml, dissolving the mixture, adding Pd/C78 mg, reducing with hydrogen, stirring at room temperature for 10 hr, TLC monitoring reaction material disappearance, stopping reaction, filtering to remove Pd/C, concentrating the reaction solution under reduced pressure, and collecting residue with 3ml CHCl3Redissolving, adding 2.2g of silica gel, evaporating to dryness under reduced pressure, mixing the sample, and eluting with petroleum ether and acetone at a ratio of 5: 1 to obtain 0.588g of white solid. m.p.: 130.0-130.8 ℃, yield 90.7%. 1H-NMR (C)DCl3)(ppm)：0.68(s，3H，H-18)，0.96(s，3H，H-19)，0.95(d，J＝ 7.5Hz，3H，H-21)，4.92(m，1H，H-3)，3.87(brs，1H，H-7)，2.72(s，3H， CH3-6′)，2.65(s，6H，CH3-3′，5′)，1.00-2.50(28H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.2(C1)，26.7(C2)，76.3(C3)， 35.2(C4)，41.4(C5)，34.5(C6)，68.5(C7)，39.6(C8)，32.8(C9)，35.1(C10)， 20.6(C11)，39.4(C12)，42.7(C13)，50.4(C14)，23.7(C15)，28.1(C16)，55.8 (C17)，11.8(C18)，22.7(C19)，35.4(C20)，18.3(C21)，31.0(C22)，30.8 (C23)，179.1(C24)；pyrazine ring：165.7(2′-C＝O)，153.9(C2′)，140.5(C3′)，149.3(C5′)，150.4(C6′)，22.5(6′-CH3)，22.0(5′-CH3)，21.4(3′-CH3).HRMS (ESI)m/z：541.36346[M+H]+，calcd.for C32H48N2O5 540.35632.
EXAMPLE 29 preparation of Compound 27
Weighing 2.19mmol of 2-bromomethyl-3, 5, 6-trimethyl pyrazine and 2.19mmol of lithocholic acid, placing in a 50ml round bottom flask, adding 25ml DMF, dissolving the mixture, adding 3mmol of potassium carbonate, stirring at 85 deg.C for 2h, monitoring by TLC that the reaction raw materials basically disappear, stopping the reaction, adding a large amount of saturated NaCl solution into the reaction solution for dispersion, extracting twice with 300ml ethyl acetate, and extracting the ethyl acetate layer with anhydrous Na2SO4Drying, concentrating under reduced pressure, dissolving the residue with 3ml chloroform, adding 2.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 6: 1 to obtain white solid 0.589 g. m.p.: 119.3-119.9 deg.C, yield 52.7%. 1H-NMR (CDCl)3)(ppm)：0.60(s，3H，H-18)， 0.89(s，3H，H-19)，0.88(d，J＝6.0Hz，3H，H-21)，3.60(m，H，H-3)，5.17(t，J ＝12.5Hz，2H，CH2-2′)，2.51(s，3H，CH3-6′)，2.49(s，3H，CH3-5′)，2.48(s，3H， CH3-3′)，1.00-2.50(29H，methyl-and methylene-of steroid structure). 13C-NMR(CDCl3)(ppm)：35.8(C1)，30.5(C2)，71.7(C3)，36.4(C4)，42.1 (C5)，27.2(C6)，26.4(C7)，40.2(C8)，34.6(C9)，35.3(C10)，20.8(C11)，40.4 (C12)，42.7(C13)，56.5(C14)，24.2(C15)，28.1(C16)，56.0(C17)，12.0 (C18)，23.4(C19)，35.4(C20)，18.2(C21)，31.1(C22)，31.0(C23)，173.8 (C24)；pyrazine ring：64.9(2′-CH2)，151.2(C2′)，144.9(C3′)，148.9(C5′)， 149.0(C6′)，21.6(6′-CH3)，21.4(5′-CH3)，20.4(3′-CH3).HRMS(ESI)m/z： 511.38754[M+H]+，calcd.for C32H50N2O3 510.38214.
EXAMPLE 30 preparation of Compound 28
Weighing about 1.2mmol of compound 27 and 1.2mmol of ligustrazine acid, placing in a 50ml round bottom flask, adding 25ml of CH2Cl2After the mixture is dissolved, EDCI 1.2mmol and DMAP 0.12mmol are respectively added, the mixture is stirred for 12h at room temperature, TLC monitors that the reaction raw materials basically disappear, the reaction is stopped, the mixture is concentrated under reduced pressure, 2.2g of silica gel is added, the mixture is evaporated to dryness under reduced pressure and mixed, and the eluent is petroleum ether and acetone which are 5: 1 for elution, so that 0.386g of oily matter is respectively obtained. m.p.: 85.3-85.9 deg.C, yield 48.9%. 1H-NMR (CDCl)3) (ppm)：0.65(s，3H，H-18)，0.97(s，3H，H-19)，0.91(d，J＝6.0Hz，3H，H-21)， 5.01(m，H，H-3)，5.20(t，J＝12.5Hz，2H，CH2-2′)，2.73(s，3H，CH3-6″)，2.58 (s，3H，CH3-5″)，2.57(s，3H，CH3-3″)，2.54(s，3H，CH3-6′)，2.53(s，3H， CH3-5′)，2.52(s，3H，CH3-3′)，1.00-2.50(28H，methyl-and methylene-of steroid structure).13C-NMR(CDCl3)(ppm)：35.8(C1)，27.1(C2)，76.3(C3)， 32.2(C4)，42.1(C5)，26.6(C6)，26.3(C7)，40.1(C8)，34.7(C9)，35.1(C10)， 20.8(C11)，40.4(C12)，42.7(C13)，56.5(C14)，24.2(C15)，28.2(C16)，56.0 (C17)，12.0(C18)，23.3(C19)，35.3(C20)，18.3(C21)，31.1(C22)，31.0 (C23)，173.9(C24)；pyrazine ring：65.0(2′-CH2)，151.2(C2′)，144.9(C3′)， 149.0(C5′)，149.0(C6′)，165.5(2″-C＝O)，154.0(C2″)，140.5(C3″)，149.2 (C5″)，150.4(C6″)，21.7(6′-CH3)，21.5(5′-CH3)，20.5(3′-CH3)，22.6(6″-CH3)， 22.1(5″-CH3)，21.7(3″-CH3).HRMS(ESI)m/z：659.45245[M+H]+，calcd. for C40H58N4O4 658.44581.
Preparation of lithocholic acid benzyl ester: weighing benzyl bromide 5.0mmol and lithocholic acid 5.0mmol, placing in 50ml round bottom flask, adding 25ml DMF, dissolving the mixture, adding 2.0mmol potassium carbonate, adding 5mmol potassium carbonate, stirring at 85 deg.C for 2 hr, monitoring by TLC that the reaction raw material basically disappears, stopping reaction, adding a large amount of saturated NaCl solution to the reaction solution for dispersion, extracting with 400ml ethyl acetate twice, extracting the ethyl acetate layer with anhydrous Na2SO4Drying, concentrating under reduced pressure, dissolving the residue with 5ml chloroform, adding 3.8g silica gel, evaporating under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 5: 1 to obtain white solid 2.125 g. White powder, m.p.: 129.1-129.8 ℃ and yield 91.2 percent.
EXAMPLE 31 preparation of Compound 29
Weighing lithocholic acid benzyl ester 3.0mmol and ligustrazine acid 3.0mmol, placing in 50ml round bottom flask, adding 30ml CH2Cl2After the mixture is dissolved, respectively adding EDCI 3.0mmol and DMAP 0.3mmol, stirring at room temperature for 12h, monitoring by TLC that the reaction raw material basically disappears, stopping the reaction, washing the reaction solution twice by 60ml of saturated NaCl solution, and obtaining CH2Cl2Anhydrous Na for layer2SO4Drying, concentrating under reduced pressure, adding 3.2g silica gel, evaporating to dryness under reduced pressure, mixing, eluting with petroleum ether and acetone at ratio of 7: 1 to obtain white solid 0.938 g. m.p.: 102.6-103.3 deg.C, yield 50.9%. 1H-NMR (CDCl)3) (ppm)：0.65(s，3H，H-18)，0.98(s，3H，H-19)，0.92(d，J＝6.5Hz，3H，H-21)， 5.06(m，H，H-3)，5.15，5.12(ea，d，J＝12.5Hz，1H，CH2-1′)，7.38(m，5H， H-2′，3′，4′，5′，6′)，2.74(s，3H，CH3-6″)，2.59(s，3H，CH3-5″)，2.58(s，3H， CH3-3″)，1.00-2.50(28H，methyl-and methylene-of steroid structure). 13C-NMR(CDCl3)(ppm)：35.8(C1)，27.1(C2)，76.3(C3)，32.3(C4)，42.1 (C5)，26.6(C6)，26.4(C7)，40.1(C8)，34.7(C9)，35.1(C10)，20.9(C11)，40.4 (C12)，42.7(C13)，56.5(C14)，24.2(C15)，28.2(C16)，56.0(C17)，12.0 (C18)，23.3(C19)，35.3(C20)，18.3(C21)，31.3(C22)，31.0(C23)，174.1 (C24)，66.1(1′-CH2)，136.1(C1′)，128.2(C2′，6′)，128.5(C3′，5′)，128.2(C4′)；pyrazine ring：165.8(2″-C＝O)，154.0(C2″)，140.6(C3″)，149.3(C5″)，150.4 (C6″)，22.6(6″-CH3)，22.1(5″-CH3)，21.7(3″-CH3).HRMS(ESI)m/z： 637.39772[M+Na]+，calcd.for C39H54N2O4 614.40836.
EXAMPLE 32 preparation of Compound 30
Weighing 291.2mmol of compound, placing in 50mL round-bottom flask, adding 30mL THF, dissolving the mixture, adding 40mg Pd/C, reducing with hydrogen, stirring at room temperature for 10h, monitoring by TLC that the reaction material is substantially disappeared, stopping the reaction, filtering to remove Pd/C, concentrating the reaction solution under reduced pressure, and adding 3ml CHCl into the residue3Redissolving, adding 2.2g of silica gel, drying by distillation under reduced pressure, mixing the sample, and eluting by petroleum ether and acetone of 5: 1 to obtain 0.583g of white solid. m.p.: 184.5-185.2 deg.C，yield 92.7％.1H-NMR (CDCl3)(ppm)：0.68(s，3H，H-18)，0.99(s，3H，H-19)，0.95(d，J＝6.5Hz， 3H，H-21)，5.07(m，H，H-3)，2.74(s，3H，CH 3-6″)，2.59(s，3H，CH 3-5″)，2.59 (s，3H，CH 3-3″)，1.00-2.50(29H，methyl-and methylene-of steroid structure). 13C-NMR(CDCl3)(ppm)：35.8(C1)，27.1(C2)，76.3(C3)，32.3(C4)，42.1 (C5)，26.6(C6)，26.4(C7)，40.1(C8)，34.7(C9)，35.1(C10)，20.9(C11)，40.4 (C12)，42.7(C13)，56.5(C14)，24.2(C15)，28.2(C16)，56.0(C17)，12.0 (C18)，23.3(C19)，35.3(C20)，18.3(C21)，31.3(C22)，31.0(C23)，174.1 (C24)，66.1(1′-CH2)，136.1(C1′)，128.2(C2′，6′)，128.5(C3′，5′)，128.2(C4′)； pyrazine ring：165.8(2″-C＝O)，154.0(C2″)，140.6(C3″)，149.3(C5″)，150.4 (C6″)，22.6(6″-CH3)，22.1(5″-CH3)，21.7(3″-CH3).HRMS(ESI)m/z： 525.36871[M+H]+，calcd.for C32H48N2O4524.36141.
Example 33
Taking 10g of the compound prepared in any one of the embodiments 3-32, adding appropriate auxiliary materials into injection (including freeze-dried powder injection and sterile subpackaged powder injection), and preparing the anti-tumor drug injection according to the injection (including freeze-dried powder injection and sterile subpackaged powder injection) process.
Example 34
Taking 10g of the compound prepared in any one of the embodiments 3-32, adding appropriate auxiliary materials into tablets (including sustained release tablets, matrix tablets, coated tablets, dispersible tablets and the like), and preparing the compound into the anti-tumor tablets according to the process of the tablets (including sustained release tablets, matrix tablets, coated tablets, dispersible tablets and the like).
Example 35
Taking 10g of the compound prepared in any one of the embodiments 3-32, adding appropriate capsule auxiliary materials, and preparing the compound into an anti-tumor capsule according to a capsule process.
Example 36
Taking 10g of the compound prepared in any one of the embodiments 3-32, adding appropriate auxiliary materials of an emulsion (including microemulsion, nanoemulsion and the like), and preparing the anti-tumor emulsion according to the process of the emulsion (including microemulsion, nanoemulsion and the like).
Example 37
Taking 10g of the compound prepared in any one of the embodiments 3-32, adding proper auxiliary materials of granules, and preparing the antitumor granules according to a granule process.
Example 38
Taking 10g of the compound prepared in any one of the embodiments 3-32, adding a proper auxiliary material of the sustained-release controlled-release agent, and preparing the sustained-release controlled-release agent of the antitumor drug according to the sustained-release controlled-release agent process.
Example 39
Taking 10g of the compound prepared in any one of the embodiments 3-32, adding proper auxiliary materials of the oral liquid, and preparing the anti-tumor oral liquid according to an oral liquid process.
Example 40
Taking 10g of the compound prepared in any one of the embodiments 3-32, adding proper auxiliary materials of a liposome formulation, and preparing the antitumor liposome formulation according to a liposome process.
Claims (8)
1. A compound having the structure of formula 1 or a pharmaceutically acceptable salt thereof:
2. a pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
3. A process for preparing a compound according to claim 1, comprising:
the hyodeoxycholic acid and 2-bromomethyl-3, 5, 6-trimethylpyrazine react under alkaline conditions, and products obtained by the reaction further react with ligustrazine acid under the action of a catalyst and a condensing agent.
4. Use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of an anti-cancer medicament.
5. The use of claim 4, wherein the cancer is liver cancer, colon cancer, cervical cancer, breast cancer.
6. A kit comprising a therapeutically effective amount of a compound of formula 1 according to claim 1 or a pharmaceutically acceptable salt thereof and an anti-cancer agent; wherein the therapeutically effective amount of the compound of formula 1 or a pharmaceutically acceptable salt thereof is 1-10 mg/kg-day.
7. The kit of claim 6, wherein said anticancer agent is any one or more of cyclophosphamide, 5-fluorouracil, paclitaxel, doxorubicin, etoposide, irinotecan, oxaliplatin, cisplatin, or gemcitabine.
8. Use of a kit according to claim 6 or 7 for the manufacture of an anti-cancer medicament.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510925321 | 2015-12-14 | ||
| CN2015109253217 | 2015-12-14 | ||
| CN201610473424 | 2016-06-24 | ||
| CN2016104734249 | 2016-06-24 | ||
| PCT/CN2016/109950 WO2017101789A1 (en) | 2015-12-14 | 2016-12-14 | Compound having anti-cancer effect, and method for preparation thereof and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108350023A CN108350023A (en) | 2018-07-31 |
| CN108350023B true CN108350023B (en) | 2021-01-08 |
Family
ID=59055730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680053558.3A Active CN108350023B (en) | 2015-12-14 | 2016-12-14 | Compound with anticancer effect and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN108350023B (en) |
| WO (1) | WO2017101789A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102106943B1 (en) * | 2018-02-05 | 2020-05-06 | 전북대학교 산학협력단 | novel macromolecular compound comprising UDCA and use thereof |
| ES2769905B2 (en) * | 2018-12-28 | 2020-12-10 | Univ Santiago Compostela | COMPOUNDS OF PHARMACEUTICAL INTEREST |
| WO2020260558A1 (en) | 2019-06-27 | 2020-12-30 | Phenex Pharmaceuticals Ag | 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases |
| CN114195853B (en) * | 2021-12-28 | 2022-12-30 | 中山百灵生物技术股份有限公司 | Allochenodeoxycholic acid derivative, and synthesis method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102675401A (en) * | 2011-03-09 | 2012-09-19 | 雷海民 | Preparation of anti-tumor medicine LQC-Y and application thereof |
-
2016
- 2016-12-14 CN CN201680053558.3A patent/CN108350023B/en active Active
- 2016-12-14 WO PCT/CN2016/109950 patent/WO2017101789A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102675401A (en) * | 2011-03-09 | 2012-09-19 | 雷海民 | Preparation of anti-tumor medicine LQC-Y and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| A Series of New Ligustrazine-Triterpenes Derivatives as Anti-Tumor Agents: Design, Synthesis, and Biological Evaluation;Bing Xu 等;《International Journal of Molecular Sciences》;20150902;第16卷(第9期);第21036-21038、21045-21048页 * |
| Synthesis and Biological Evaluation of New Ligustrazine Derivatives as Anti-Tumor Agents;Penglong Wang 等;《Molecules》;20120430;第17卷(第5期);第4974页化合物5和6，第4975页 * |
| 新型川芎嗪衍生物的合成及其抗癌活性研究;王鹏龙 等;《西北药学杂志》;20140110;第29卷(第1期);全文 * |
| 齐墩果酸和去氧胆酸衍生物合成及抗血管生成活性研究;王鹏龙 等;《首都医科大学学报》;20120821;第33卷(第4期);第495页图3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017101789A1 (en) | 2017-06-22 |
| CN108350023A (en) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102675401B (en) | Preparation of anti-tumor medicine LQC-Y and application thereof | |
| CN108350023B (en) | Compound with anticancer effect and preparation method and application thereof | |
| CN105315321B (en) | Compound and its preparation method and application with antitumor action | |
| EP1916251A1 (en) | Erianin salts, their preparation methods and pharmaceutical compositions containing the same | |
| CN106866572B (en) | Nitric oxide donator type β elemene derivatives and its production and use | |
| CN106478760B (en) | Three note analog derivative TBA-X with antitumor action and its preparation method and application | |
| CN101074189B (en) | Styrene acid derivative and use in preparation of various blood-vessels target agent medicine | |
| CN101402667B (en) | Glycosylation-modified nitric oxide-donating oleanolic acid compound, its preparation method and use | |
| CN107216283B (en) | A kind of beta-elemene derivatives and its preparation method and application containing dihydropyridine structure | |
| CN110857295A (en) | Flavone-ligustrazine compound CH-X with selective anti-liver cancer effect and preparation method and application thereof | |
| CN111471080B (en) | ocotillol type ginsengenin A-ring amino thiazole ring derivative and preparation method thereof | |
| CN108137644B (en) | Compound with anti-tumor effect and preparation method and application thereof | |
| CN104151388B (en) | The preparation of antitumor drug LQC-Y and application thereof | |
| CN107474097A (en) | With antitumor action enoxolone cinnamic acid derivative（GA‑CA）Preparation method and applications | |
| CN116063372A (en) | Mitochondria-targeted antitumor compound, and preparation method and application thereof | |
| CN110922450B (en) | PSMA activated antitumor prodrug CPT-X and preparation method and application thereof | |
| CN109867709B (en) | Preparation method and application of glycyrrhetinic acid series derivatives (TOGA-X) with anti-tumor effect | |
| CN117088772B (en) | A kind of steviol derivative and its preparation method and application | |
| CN102838652B (en) | A kind of oleanolic acid derivate with anticarcinogenesis and its production and use | |
| WO2023160543A1 (en) | Methods of synthesis and uses of agrimol compounds | |
| CN115160399B (en) | Soap-skin acid compound, preparation method and medical application thereof | |
| US8822441B2 (en) | Ecdysterone synthesis derivative, preparation method and use thereof | |
| CN119350423A (en) | A kind of bufotoxin bisphosphate derivative and its application | |
| CN103204897B (en) | 3,12 the soladulcine derivatives modified, its preparation method, preparation and medicinal uses thereof | |
| CN107325030A (en) | The new trans-stilbene class antitumor agent of one class |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: No. 1201, 12 / F, unit 1, building 1, No. 318, Xishun street, huazhaobi, Jinniu District, Chengdu, Sichuan 610036 Patentee after: Sichuan thought Kangrui Pharmaceutical Co.,Ltd. Address before: No. 64-66, Jiaogui Lane 2, Jinniu District, Chengdu, Sichuan 610031 Patentee before: 3D MEDICINES (SICHUAN) Co.,Ltd. |